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ABSTRACT 
Regulatory T cells (Treg) are the master immune-suppressor cells, with a double-edged 
sword. Treg protect us from autoimmunity, damages from excessive inflammation, and 
help us maintaining homeostasis in mucosal surface. On the other hand, Treg can be 
negative force against anti-tumor immunity in the tumor microenvironment (TME), 
which need to be targeted to maximize the effects of cancer immunotherapies. However, 
the exact phenotype and molecular basis of suppressive function of Treg in the TME have 
not been fully elucidated. Especially of translational relevance; what is the phenotype of 
tumor-infiltrating Treg (TIL-Treg) under the fundamental cancer therapy such as 
radiotherapy, and what is the determinant molecules for human TIL-Treg have not been 
fully elucidated. 
To answer those questions, in my thesis projects, I have elucidated the TIL-Treg 
phenotype post radiotherapy (RT), and discovered novel human TIL-Treg targeting 
molecules.  
In RT-Treg project, we have shown that RT significantly increased the phenotypically 
activated and, importantly functionally suppressive Treg in the TME. To the best of our 
knowledge, we were the first to demonstrate that irradiated TIL-Treg are indeed 
functionally suppressive, using the in vitro micro-suppression assay, using TIL post-RT. 
Our results also suggest that post-RT Treg expansion is likely independent of TGF-beta 
nor IL-33, but at least partly due to the proliferation of the Treg in the tumor. 
In human TIL-Treg project, we performed RNAseq from prostate cancer, glioblastoma 
and renal cell carcinoma (and urothelial carcinoma as well) patients and identified novel 
targets highly expressed in TIL-Treg, including DUSP1, DUSP4, RGS1 (and RGS16). 
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Despite its high expression in Treg, DUSP1 showed unique downregulation upon 
activation, which presents a stark contrast with most Treg-associated molecules many of 
which increase their expression in activation. DUSP1 accordingly showed reciprocal 
expression pattern with DUSP4. From the data and close homology with DUSP1 and 
DUSP4, I hypothesized that DUSP1 and DUSP4 reciprocally regulate Treg activation and 
function. In depth in vitro and in vivo studies are underway to further elucidate the 
functional roles of these molecules in TIL-Treg (and TIL). 
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CHAPTER I: Introduction 
I-1: Cancer immunology, the tumor microenvironment and cancer
immunotherapies 
Today we are facing the unprecedented bursting development and the prime time of 
cancer immunotherapy; when the numbers of immunotherapies have been developed and 
approved in clinic, where the liaison of basic, translational and clinical research are 
making spiral progress and changing the clinical practice and patients outcome. The 
history of cancer immunology dates back in 1909, when Paul Ehrlich predicted that the 
immune system repressed the growth of carcinoma1, revisited by Lewis Thomas and 
Frank Macfarlane Burnet in late 1950s2-4. The interaction of immune system and the 
tumor microenvironment (TME) was further systemized by Schreiber et al. as “cancer 
immunoediting” theory, which is a dynamic process composed of three phases: 
elimination, equilibrium, and escape5,6.  
Tumor progression or regression are determined by the tip of the balance of host anti-
tumor immunity versus immune suppression in the TME (Figure I-1). Host anti-tumor 
effects come from the collaboration of innate and adaptive immune system; for innate 
immunity, danger signals released from tumors activate innate immunity including 
STING pathways, and release pro-inflammatory cytokines, and type I IFN. NK cell, M1 
macrophage also play roles in tumor cell killing7,8. For adaptive immunity side, tumor 
antigen presentation followed by the tumor antigen specific activation of T cell response, 
leading to the secretion of IFN-g, Granzyme B for tumor killing, is of high importance. 
However, the TME also harbors numbers of immune suppressive mechanisms to evade 
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host immune attacks to protect themselves; including, lack of antigen presentation from 
tumor cells, impairment of T cell activation by expression of immune checkpoints 
(including CTLA-4, PD-1/PD-L1, LAG3, TIM-3, VISTA)9, secretion of suppressive 
cytokines including TGF-beta, IL-10, IL-35, metabolic changes, and numbers of immune-
suppressive cells such as tumor associated macrophages (TAM), Myeloid-derived 
suppressor cells (MDSC), and importantly, regulatory T cells (Treg)10.  
Cancer immunotherapy have been attempting to boost the anti-tumor immunity of host to 
eradicate tumors either by stimulating anti-tumor effects; the approaches include vaccines, 
adjuvant, agonists, or adoptive T cell transfer, or notably, by releasing breaks from 
suppressive immunity by targeting the above mentioned suppressive mechanisms, and the 
combination of both and with other pillars of cancer therapies including radiotherapy (RT) 
and chemotherapy. Among them, the most clinically successful approaches have been the 
immune checkpoint blockades11-13, one of the latter approaches to releasing 
immunosuppressive breaks. Numbers of immune checkpoints, especially CTLA-4 and 
PD-1 targeted therapies to unleash the activated T cell responses, are now in clinic, and 
there have been floods of clinical trials of anti-CTLA4 and anti-PD-1/PD-L1 therapies 
and they have been approved by FDA in different types of tumors (Muroyama, LaFleur, 
Drake, Sharpe. J. Immunol (2018))10,14 (Figure I-2, Table I) 
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Table 1: FDA approved Anti-PD-1/PD-L1 Agents





Melanoma, NSCLC, Hodgkin 






Melanoma, NSCLC, Hodgkin 
lymphoma, RCC, Urothelial 











Avelumab Fully human IgG1 lambda 
Urothelial carcinoma, Merkel cell 
carcinoma
Table 1: FDA approved Anti-PD-1/PD-L1 Agents 
Abbreviations: NSCLC: Non-Small Cell Lung Cancer, HNSCC: Head and Neck Squamous Cell 
Carcinoma, MSI-H: microsatellite instability-high, dMMR: mismatch repair deficient, RCC: Renal 
Cell Carcinoma
Despite the unprecedented successful cases and response rates of immunotherapies, 
numbers of cases are still refractory to the therapies; subsets of tumors are not 
immunogenic and with poor response rate (including prostate cancers, pancreatic cancers), 
and some patients experience relapse post immunotherapies. Therefore, understanding 
the mechanisms of resistance and developing the strategies to overcome resistance, 
making “cold/non-inflamed” tumors into “hot/inflamed” tumors have been huge 
challenges7,10. 
Many of the mechanisms of resistance overlap with the suppressive immune response 
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mentioned above, and recent clinical focus is also on mutational burden; low mutational 
burden could leading to low neo-antigen burden which could prime less tumor antigen 
specific T cells10,15, and other factors of intervention are the active and intense area of 
research both in clinical and preclinical studies10. And among them, regulatory T cells 
(Treg) are the major immune suppressor of high importance, as described in the following 
section, and understanding the nature and molecular mechanism of Treg in tumors as well 
as developing Treg-targeted therapies are of vital translational and clinical importance to 
overcome resistance and maximize the effect of cancer immunotherapies. 
I-2: Regulatory T cells (Treg), especially in the tumor-microenvironment (TME)
Regulatory T cell (Treg) is a subset of T cell with suppressive function, which plays an 
important role to avoid auto-immunity and maintain homeostasis by suppressing 
excessive inflammation. The key master regulator of Treg is Foxp316, which endows Treg 
the distinct gene signatures for their suppressive functions (including CTLA4, CD25…)17. 
Indeed, genetic mutations in Foxp3 are reported to impair Treg development and cause a 
fatal multi-organ autoimmune disease called immune dysregulation, polyendocrinopathy, 
enteropathy, and X-linked (IPEX) syndrome18 in human. Treg depletion in mouse models 
also represent autoimmune diseases19. Treg exert immune suppressive functions in a 
variety of ways20,21; for example, Treg have high expression of CTLA-4, which interact 
with CD80/86 on antigen-presenting cells (APC), with higher affinity than CD28 on T 
cells, and down-regulating the co-stimulatory signal required for full T cell activation, 
making effector T cells anergic22. Treg can also deplete IL-2, a cytokine required for T 
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cell growth and activation, from surrounding environment via high expression of CD25 
(IL-2R), outcompeting other T conventional cells (Tconv). Treg can also secrete numbers 
of immune-suppressive cytokines and molecules, including IL-10, TGF-beta, IL-35. Treg 
also express CD39 and CD73, converting ATP into adenosine, and some reports suggest 
that Treg can secrete granzymes to mediate killing of Tconv and APC20,21.  
This immune-suppressive nature of Treg is a double-edged sword. Treg play important 
roles in preventing auto-immunity, curtailing excessive inflammation, maintaining 
homeostasis including in the mucosa23. In human, adoptive transfer of Treg has actually 
ameliorated type I diabetes24. On the other hand, in the situation with cancers, as 
mentioned above, tumors take advantage of Treg suppression to protect themselves from 
the attacks from the host immune systems. In pre-clinical models, depletion of Treg 
results in better tumor control with activation of effector T cells25-27. In humans, Treg 
infiltration in tumor and low CD8/Treg ratio are reported to correlate with poor prognosis 
in patients in some types of cancers20,28,29, depletion of Treg by low dose 
cyclophosphamide have shown better anti-tumor response30,31 , and the treatments with 
anti-CTLA4 antibody have shown clinical response in different types of tumors including 
melanoma and now became established FDA-approved therapy32,33.  
Therefore, understanding the phenotype and molecular function of Treg in the TME and 
developing Treg-targeted immunotherapy are of high importance to maximize the anti-
tumor immunity. 
However, the nature of Treg in the TME has not been fully elucidated yet especially under 
the effects of cancer therapy including radiotherapy and the nature of Treg in human 
tumors. 
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Therefore, the objectives of my thesis projects are in two-fold; 
(1) Elucidating the effect of radiotherapy (RT) on Treg in the TME
(2) Identifying the novel targets of human TIL-Treg
(1) The realistic and practical clinical approaches to optimize the efficacy of cancer
immunotherapies will be combining them with other pillars of cancer therapies, such as 
chemotherapy and radiotherapy. With technical advancement, delivery of radiation 
become more targeted with better safety and efficacy profile. And accumulating evidence 
suggest that radiotherapy (RT) have numbers of anti-tumor immune-stimulatory effects, 
both in innate and adaptive immunity. However, not much has been known for the impact 
of suppressive immune phenotype including Treg, which needed to be targeted. Therefore, 
the overall goal of this project is to elucidate the effect of RT on Treg in the TME and 
characterize them both phenotypically, functionally and mechanistically. 
(2) The nature of human TIL-Treg and the potential therapeutic targets selectively
expressed in TIL-Treg or with beneficial immunomodulatory impacts have not been 
elucidated. From RNAseq data, we have identified novel HUMAN TIL-Treg targets with 
unique kinetics and of potential novel therapeutic targets, which are of important clinical 
and translational relevance. 
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CHAPTER II: MATERIAL AND METHODS 
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II-1: Material and Methods for Chapter III
Experimental Animals 
C57BL/6J and BALB/cJ mice were purchased from The Jackson Laboratory (Bar Harbor, 
ME). Female mice 4-8 weeks in age were used. To provide a congenic marker for cells 
used in suppression assays, 4-8 week-old, sex-matched CD45.1 (B6-Ly5.1/Cr) mice were 
purchased from Charles River Laboratories (Boston, MA). In some studies, Treg were 
isolated using sex-matched mice that express GFP under the control of the Foxp3 
promoter (B6.129(Cg)-Foxp3tm3(DTR/GFP)Ayr/J), referred hereafter as Foxp3 reporter mice19. 
A breeding pair was purchased from The Jackson Laboratories, and experimental animals 
were bred in-house.  Animals were bred and housed in specific pathogen-free facilities 
accredited by the American Association for the Accreditation of Laboratory Animal Care 
(AAALAC) with protocols approved by the Animal Care and Use Committee of the Johns 
Hopkins University School of Medicine (Baltimore, MD).  
Cell lines 
B16/F10, MC38, and RENCA cell lines were purchased from ATCC (Manassas, VA): 
B16/F10 and RENCA were cultured in complete RPMI (RPMI (Mediatech, Inc., 
Manassas, VA) with 10 % Fetal Bovine Serum (Gemini Bio-Products, West Sacramento, 
CA), 1 % anti-biotic/anti-mycotic solution (Sigma-Aldrich, St. Louis, MO), 1 % sodium 
pyruvate (Sigma-Aldrich), and 1 % MEM non-essential amino-acids (ThermoFisher 
Scientific, Waltham, MA). MC38 cells were cultured in complete DMEM (DMEM 
(Mediatech Inc.) with 10 % Fetal Bovine Serum (Gemini Bio-Products), 1 % anti-
biotic/anti-mycotic solution (Sigma-Aldrich), 1 % sodium pyruvate (Sigma-Aldrich) and 
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1 % MEM non-essential amino-acids (ThermoFisher Scientific)) in 37°C, 5 % CO2 
incubator. 
Flow cytometry 
Single-cell suspensions of tumor-infiltrating lymphocytes (TILs), draining lymph nodes 
(DLNs), and spleens were prepared as previously described34. Briefly, suspensions were 
prepared by mechanical dissociation, followed by density gradient centrifugation on an 
80 % /40 % Percoll (GE Healthcare, Pittsburgh, PA) gradient. Cells were Fc-blocked with 
purified rat anti-mouse CD16/CD32 antibody (Clone: 2.4 G2, Becton Dickinson (BD), 
La Jolla, CA) for 30 minutes in 4°C.  Dead cells were discriminated using the 
LIVE/DEAD® (LD) Fixable Near-IR Dead Cell Stain Kit (ThermoFisher Scientific) and 
samples were stained with the following antibodies: CD3 (Clone 17A2, Biolegend, San 
Diego, CA), CD4 (Clone RM4-5, ThermoFisher Scientific), CD8a (Clone 53-6.7, 
Biolegend), Foxp3 (Clone FJK-16s, eBioscience, San Diego, CA), CCR4 (Clone 2G12, 
Biolegend), 4-1BB (Clone 17B5, Biolegend), Ki-67 (Clone SolA15, Biolegend), CTLA-
4 (Clone UC10-4B9, Biolegend), Helios (Clone 22F6, Biolegend). Stained samples were 
analyzed on an LSR II flow cytometer (BD).  Flow data were quantified using FlowJo 
software (FlowJo, LLC, Ashland, OR). 
Radiotherapy (RT) 
Palpable tumors were irradiated with 10 Gy using the Small Animal Radiation Research 
Rlatform (SARRP; Xstrahl, Suwanee, GA) as previously described35. Briefly, mice with 
palpable subcutaneous tumors (B16/F10, RENCA, and MC38) were anesthetized with 
isoflurane and treated with SARRP radiotherapy (RT). 7-days post radiation, tumors, 
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DLNs and spleens were harvested, and analyzed by flow-cytometry. 
Tumor growth and TIL preparation 
On day 0, 5x105 B16/F10, 1.5x106 MC38 or 3x105 RENCA cells were implanted 
subcutaneously (s.c.) to the flank of either wild-type C57BL/6J mice (in B16/F10 or 
MC38 experiments) or wild-type Balb/c mice (in RENCA experiments). On either day 7 
(B16/F10), day 16 (RENCA) or day 10 (MC38), mice received 10 Gy of stereotactic 
radiation (RT) via the small animal radiation research platform (SARRP). 7 days after RT, 
mice were sacrificed.  Tumors, DLNs, and spleens were harvested and used for flow 
cytometry analysis. Tumor diameters were measured every 2 to 3 days with an electronic 
caliper and are reported as volume using the formula (W2 x L)/2, where W represents the 
shorter diameter and L stands for the longer tumor diameter.  
Immunohistochemistry (IHC) 
Immunostaining for Foxp3 was performed on formalin-fixed, paraffin-embedded sections. 
Briefly, following dewaxing and rehydration, slides were immersed in 1% tween-20, and 
heat-induced antigen retrieval was performed in a steamer using Target Retrieval Solution 
(Dako, Santa Clara, CA) for 45 minutes. Slides were rinsed in PBST and endogenous 
peroxidase and phosphatase was blocked with Dual Endogenous Enzyme Block (Dako) 
and sections were then incubated with primary antibody; Foxp3 Rabbit monoclonal 
antibody (Clone D6O8R, Cell Signaling, Danvers, MA) for 45 minutes at room 
temperature. The primary antibodies were detected via a 30 minute incubation with HRP-
labeled secondary antibody (Leica Microsystems, Buffalo Grove, IL) followed by 
detection with 3,3′-Diaminobenzidine (Sigma-Aldrich), counterstaining with Harris 
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hematoxylin, rehydration and mounting. 
In vitro suppression assays (micro-suppression assay) 
Small-cell number suppression assays were performed as previously described36. To 
reliably sort Treg from spleen and tumors, Foxp3 reporter mice (B6.129(Cg)-
Foxp3tm3(DTR/GFP)Ayr/J) were used19. These mice were used for isolation of GFP-positive 
Treg, not for Treg-depletion. 5x105 B16/F10 cells were implanted s.c. into Foxp3 reporter 
mice. Mice were irradiated, and tumors and spleens were harvested as described above. 
TIL-Treg and spleen Treg from Foxp3 reporter mice were sorted as CD4+ GFP+ (CD4+
Foxp3+) cells; while congenically marked responder cells (Tresponder) from the spleen 
and inguinal lymph nodes of CD45.1 (B6-Ly5.1/Cr) mice were sorted as CD45.1+ CD4+ 
CD25- . Antigen presenting cells (APCs) were sorted as CD4- Foxp3- cells from spleen of 
Foxp3 reporter mice. Cells were sorted on a Fluorescence-Activated Cell Sorter (FACS) 
Aria II (BD, La Jolla, CA). Sorted responder cells were stained with CellTrace Violet 
(CTV; ThermoFisher Scientific) and plated in a in a 96-well round-bottom plate at a 
density of 2 x 104 responder cells per well. GFP+ Treg cells were added at 2-fold dilutions 
starting from 1 x 104 cells, in the presence of mitomycin C-fixed (Sigma-Aldrich), 4 x 104 
APCs, and 1 µg/ml anti-CD3 (Clone: 145-2C11, Biolegend) and incubated for 80-90 
hours. Proliferation of responder cells (gated as L/D-CD4+CD45.1+Foxp3-) was 
quantified by flow cytometry based on the dilution of Cell Trace Violet (CTV). Percent 
suppression (% Suppression) was calculated by the following formula. % Suppression = 
(1-(% divided cells of the condition/ the average of % divided cells of Tresponder only 
conditions)) x 100. 
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TGF-β inhibition 
Galunisertib (LY2157299; Selleck Chemicals, Houston, TX) or vehicle (10 g glucose, 30 
g Cremophor, 30 g polyethylene glycol, 10 ml ethanol, and 30 ml distilled water) were 
delivered 300 mg/kg/day in a volume of 100 µl via oral gavage every 12 hours, starting 
one day prior to RT and continued until the day of harvest. 
IL-33 signaling blockade 
Mouse anti-ST2/IL-33 R monoclonal antibody (Clone 245707, R & D, Minneapolis, MN) 
was diluted in PBS and administrated intraperitoneally at a concentration of 200 µg in a 
volume of 100 µl per mouse every three days37, starting one day before RT, for a total of 
three doses. 
Fingolimod experiments 
Fingolimod (FTY720, Enzo Life Sciences, Farmingdale, NY) was prepared and 
administered as previously described38. Briefly, mice received a dose of 25 μg FTY720 
or vehicle (PBS containing DMSO) via oral gavage in a volume of 100 µl per mouse 
every 3 days, starting one day prior to RT, for a total of three doses. Sequestration of 
peripheral lymphocytes was monitored using the Hemavet whole blood cell counter 
(Drew Scientific, Miami Lakes, FL). 
Luminex assays and ELISA 
Tumors collected at different post-radiation time points were minced, lysed in CelLyticTM 
MT (Sigma, St. Louis, MO) containing halt protease and phosphatase inhibitor 
(Thermofisher Science) in a 1:100 ratio, and incubated on ice for 30 minutes with 
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intermittent vortexing.  Tumor lysates were assayed for raw protein concentration with 
Coomassie assay (Bio-Rad, Hercules, CA). A panel of cytokines and chemokines (IL-2, 
Exodus-2/CCL21/6Ckine, MCP-5/CCL12, Fractalkine/CXCL1, TARC/CCL17, MIP-3β, 
MCDC/CCL22, MIP-3α/CCL20, Eotaxin/CCL11, MIP-1α/CCL3, MIP1β/CCL4, MIP-
2/CXCL2, MCP-1/CCL2, MIG/CXCL9, RANTES/CCL5, IP-10/CXCL10) was analyzed 
using a Millipore Mouse Cytokine/Chemokine Panel (Millipore, Billerica, MA). In 
addition, TGF-β and IL-33 were analyzed using a Milliplex map Kit (Millipore), and a 
Mouse/Rat IL-33 Quantikine ELISA Kit (R & D), respectively. 
NanoString 
RNA extraction was performed using the TRIzol reagent (ThermoFisher Scientific, 
Waltham, MA) as per manufacturer's instructions. For NanoString analysis, the nCounter 
mouse PanCancer Immune Profiling panel was employed using the nCounter Analysis 
System (both NanoString, Seattle, WA). Analysis was conducted using nSolver software 
(NanoString). 
Statistical Analyses 
Group means were compared with Student’s t tests. Tumor growth and lymphocyte counts 
in the Fingolimod experiment were analyzed using two-way ANOVA with multiple 
comparisons. All statistical tests were two-sided, and p values equal or below 0.05 were 
considered statistically significant. All analyses were conducted using GraphPad Prism 5 
(GraphPad Software Inc., La Jolla, CA). 
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II-2: Material and Methods for Chapter IV
Human tissue processing and RNAseq: 
Details of RNAseq and human tumor sample processing will be described in the paper by 
Thomas Nirschl, Yuki Muroyama, Charles Drake et al (in preparation/ close to 
submission).  
PBMC Preparation 
30 CC’s of whole blood was collected from each patient prior to surgery and was 
processed within 2 hours of collection. Whole blood was diluted with 10mL of 1X HBSS 
(Corning cellgro; Manassas, VA Ref. 21-022-CV) and underlayed with 10mL of Ficoll-
Paque Premium (GE Healthcare; Pittsburgh, PA Ref. 17-5442-03), then centrifuged at 
2000 rpm (913 RCF) for 20 minutes at room temperature (RT) without application of the 
break. The buffy coat was then extracted for downstream application.  
Tumor Dissociation 
Fresh tumor tissue from patients underwent prostatectomies was obtained 
immediately following the surgical procedure. On average, between 150mg and 250mg 
of tissue was obtained. Tissue was mechanically separated into 2-4mm cubes and 
transferred to gentleMACS C Tubes (Miltenyi Biotec; Bergisch Gladbach, Germany Ref. 
130-093-237). Tissue samples were processed in accordance with the human tumor
dissociation kit (Miltenyi Biotec; Bergisch Gladbach, Germany Ref. 130-095-929), then 
were placed on the gentleMACS Octo Dissociator (Miltenyi Biotec; Bergisch Gladbach, 
Germany Ref. 130-095-929) and run using the protocol 37C _h_TDK _1 per Miltenyi 
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protocol. Single cell suspensions were made for downstream applications. 
T cell Enrichment 
Cells from both PBMC and Tumor sources were then enriched using Dynabeads 
FlowComp Human CD4 Kits (Thermo Fisher Scientific; Waltham, MA Ref. 11331D) and 
Dynabeads FlowComp Human CD8 Kits (Thermo Fisher Scientific; Waltham, MA Ref. 
11333D) simultaneously in accordance with kit protocols except for not using positive 
enrichment targeting the CD3 receptor to avoid accidental activation of T cells prior to 
FACS enrichment.  
FACS sorting 
Described in the following section. 
Ex-Vivo T cell Activation 
Described in the following section. 
RNA-Sequencing 
Whole transcriptome expression analysis (RNA-seq) was performed on an Illumina 
HiSeq instrument, using 100 bp paired end sequencing generating an average of 50 
million reads per analyzed sample. 
Bioinformatic Analysis 
For data preprocessing, raw reads were cleaned for PCR artifacts and adapter trimmed 
then aligned with the human genomes using the bowtie2 algorithm. Gene and isoform 
expressions for each sample were obtained using the RSEM/EBseq tool suite. A 
generalized linear model approach was applied, incorporating patient information to 
identify genes differentially expressed between T-cell sub-populations. Gene Set 
Enrichment Analysis was used to identify pathways differentially expressed and social 




Dusp1 floxed mice and Rgs1 floxed mice were generated by Ozgene (Perth, Australia). 
 
Mouse tumor model:  
On day 0, 5x105 B16/F10 cells were implanted subcutaneously (s.c.) to the flank of GFP-
Foxp3 mice, which express GFP under the control of the Foxp3 promoter referred to as 
GFP-Foxp3 mice(ref). A breeding pair was purchased from The Jackson Laboratories, 
and experimental animals were bred in-house as described in Chapter I. And tumor, DLN 
and spleen were harvested as described in Chapter I. 
 
FACS sorting 
Human cells; Enriched T cells from both PBMC and Tumor(TIL) sources, or thawed 
healthy donor-derived frozen PBMC were then stained with the following antibodies: 
Pacific Blue-CCR7 (BioLegend; San Diego, CA, Ref. 353210), Blue-CCR7 (BioLegend; 
San Diego, CA, Ref. 353210), Brilliant Violet 570-CD45RO (BioLegend; San Diego, CA, 
Ref. 304226), Alexa Fluor 488-CD127 (BioLegend; San Diego, CA, Ref. 351314), PE-
CD25 (BioLegend; San Diego, CA, Ref. 302606), PerCP-Cy5.5-CD45RA (BioLegend; 
San Diego, CA, Ref. 304122), PE-Cy5-CD4 (BioLegend; San Diego, CA, Ref. 317412), 
PE-Cy7-CD8 (BioLegend; San Diego, CA, Ref. 300914), APC-CD28 (BioLegend; San 
Diego, CA, Ref. 302912), APC-Cy7-CD27 (BioLegend; San Diego, CA, Ref. 302816). 
Target populations were defined as following: PBMC CD4 naïve 
(CD4+CD25LowCD127+/-CCR7+CD45RA+CD27+CD28+), PBMC CD4 regulatory T cell 
(Treg)(CD4+CD25HiCD127Low), PBMC CD8 naïve (CD8+CD45RA+CD45RO-
CD27+CD28+), PBMC CD8 antigen experienced (CD8+ CD45RA-CD45RO+), TIL CD4 
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regulatory T cell (CD4+CD25HiCD127Low) and TIL CD8 antigen experienced 
(CD8+CD45RA-CD45RO+).  
Mouse cells; Mouse splenocytes and TIL from GFP-Foxp3 mice (described below) were 
stained with the following antibodies: PerCP-Cy5.5-CD4 (Biolegend), PE-Cy7-
CD8(Biolegend), Pacific Blue- CD44 (Biolegend), APC-CD62L (Biolegend). 
Target populations were defined as following: CD4 naïve (CD4+CD62+CD44-), Treg 
(CD4+Foxp3+), CD8 naïve (CD8+CD62+CD44-) and CD8 antigen experienced 
(CD8+CD62-CD44+). 
Cells were sorted on a Fluorescence-Activated Cell Sorter (FACS) Aria II (BD, La Jolla, 
CA) or MoFlo (BECKMAN COULTER, Indianapolis IN). 
Frozen human PBMC: 
Frozen healthy human derived PBMC was obtained from the buffy coat of LeukoPak 
(New York Blood Bank Center, NY) and stored in liquid nitrogen tank with freezing 
media (10% DMSO and 90% FBS). In prior to use, they were thawed and incubated in 
cRPMI (the same as Chapter IV) overnight.  
In vitro T cell activation 
Human cells: PBMC CD4 naïve and PBMC CD8 naïve (both from fresh and frozen 
samples) were activated ex-vivo using anti-CD3/anti-CD28 activation beads (Thermo 
Fisher Scientific; Waltham, MA Ref. 111.32D). Cells were plated in 96 well round bottom 
plates (TPP; Trasadingen, Switzerland, Ref. 92097) at a concentration of 150,000 cells 
per well in complete RPMI media for 72 hours (or 12 hours in time-course experiments). 
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Stimulatory beads were used at a 5 Beads to 1 Cell ratio in accordance to previous 
experiments for maximal stimulation (unpublished).  
Mouse cells: Dynabeads™ Mouse T-Activator CD3/CD28 for T-Cell Expansion and 
Activation (ThermomFisher Scientific) were used in accordance with manufacture’s 
instructions. 
 
RNA extraction and qPCR 
RNA extraction was performed using the TRIzol reagent (ThermoFisher Scientific, 
Waltham, MA), and the isolated RNA was used to synthesize cDNA with RNA to cDNA 
EcoDry Premix Random Hexamers (Takara Bio USA, Inc., Mountain View, CA) the and 
TaqMan probes (listed below) and Universal Master Mix No UNG (Both from 
ThermoFisher Scientific) were used for quantitative RT-PCR. PCRs were performed in 
triplicate. The following primers were used:  
 
Table 2: q-PCR primers used (ThermoFisher Scientific (lifetechnologies)) 
pPCR was performed on Applied Biosystems StepOne Plus (ThermoFisher Scientific). 
Dusp1 TaqMan Probe (Human) Hs00610256_g1 
Dusp1 TaqMan Probe (Mouse) Mm00457274_g1 
Dusp4 TaqMan Probe (Human) Hs01027785_m1 
Dusp4 TaqMan Probe (Mouse) Mm00723761_m1 
Rgs1 Taqman PRgsobe (Human) Hs01023772_m1 
Rgs1 Taqman PRgsobe (Mouse) Mm00450170_m1 
Rgs16 TaqMan PRgsobe (Human) Mm00803317_m1 
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Rgs16 TaqMan PRgsobe (Mouse) Hs00892674_m1 
Foxp3 TaqMan Probe (Human) Hs01085834_m1 
Foxp3 TaqMan Probe (Mouse) Mm00475162_m1 
Granzyme B Taqman Probe (Human) Hs00188051_m1 
METRNL TaqMan Probe (Human) Hs00417150_m1 
METRNL TaqMan Probe (Mouse) Mm00522681_m1 
Tnfrsf9 Taqman Probe (Human) Hs00155512_m1 
Tnfrsf9 Taqman Probe (Mouse) Mm01268456_m1 
CCR6 Taqman Probe (Human) Hs01890706_s1 
Gapdh Taqman Probe (Human) Hs02758991_g1 
siRNA and Treg isolation 
siRNA oligos listed below, as well as positive control and negative control (Stealth 
RNAi™ siRNA GAPDH Positive Control, scramble oligos in BLOCK-iT™ Transfection 
Optimization Kit, respectively. ThermoFisher Scientific) were transfected to human 
PBMC (LeukoPak) at 200 nM by Amaxa® Human T Cell Nucleofector® Kit 
(Unstimulated) using Amaxa Nucleofactor II (both from LONZA, Basel, Switzerland) 
per manufacture’s instructions. Transfection optimization was conducted using BLOCK-
iT™ Transfection Optimization Kit (ThermoFisher Scientific). 24 hours post-transfection 
(in time-course experiments up to 96 hours), Treg were isolated by EasySep™ Human 
CD4+CD127lowCD25+ Regulatory T Cell Isolation Kit (STEMCELL, Vancouver, BC, 
Canada) and used for the downstream application including RNA extraction.  
Table 3: siRNA oligo used for transfections 
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Target gene siRNA oligo 
Dusp1 Human stealth siRNA HSS102983 
Dusp1 Human stealth siRNA HSS102984 
Dusp1 Human Stealth siRNA VHS40581 
Dusp1 Human Stealth siRNA VHS40583 
Dusp4 Human Stealth siRNA VHS40973 
Dusp4 Human Stealth siRNA VHS40975 
Rgs1 Human Stealth siRNA HSS143614 
Rgs1 Human Stealth siRNA HSS143615 
Rgs1 Human Stealth siRNA HSS143616 
Foxp3 Human Stealth siRNA HSS121456 
Foxp3 Human Stealth siRNA HSS121458 
Foxp3 Human Stealth siRNA HSS181786 
Ikzf2 (Helios) Human Stealth siRNA HSS117670 
Ikzf2 (Helios) Human Stealth siRNA HSS117672 
Ikzf2 (Helios) Human Stealth siRNA HSS176945 
(Note: The purity post Treg isolation by the above mentioned kit was poor.) 
In vitro micro-suppression assay for human Treg 
Healthy donor derived frozen PBMC (LeukoPak) were thawed and rest overnight in 
cRPMI for recovery. Treg were sorted as CD4+CD25+CD127- population, APC were 
sorted as the size of myeloid gate based on forward and side scatter. Responder cells were 
sorted as CD8+CD45RO- cells or isolated by CD8 T cell naïve selection kit (STEMCELL). 
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Cells were sorted on a Fluorescence-Activated Cell Sorter (FACS) Aria II (BD, La Jolla, 
CA) or MoFlo (BECKMAN COULTER, Indianapolis IN). When frozen samples were 
used, Treg were treated with 200 U/ml of human recombinant IL‐2 (Peprotech, Reckey 
Hill, NJ) for 1‐2 days before setting up the assay for recovery and treat the CD8 T cell 
responder population with 20 U/ml of IL‐2 for 1‐2 days for recovery of the population. 
Sorted responder cells were stained with CellTrace Violet (CTV; ThermoFisher 
Scientific) and plated in a in a 96-well round-bottom plate at a density of 2 x 103 responder 
cells per well. Treg cells were added at 2-fold dilutions starting from 1 x 103 cells, in the 
presence of 2 x 103 APCs, and 0.5-1 µg/ml anti-CD3 (Clone: OKT3, eBioscience) and 
incubated for 72-96 hours. Proliferation of responder cells was quantified by flow 
cytometry based on the dilution of Cell Trace Violet (CTV). Percent suppression (% 
Suppression) was calculated by the following formula. % Suppression = (1-(% divided 




CHAPTER III:  STEREOTACTIC 
RADIOTHERAPY INCREASES 
FUNCTIONALLY SUPPRESSIVE 




Radiotherapy (RT) is an important component of cancer treatment, with 
approximately 50% of cancer patients receiving RT as part of their treatment regimen39. 
Although the primary anti-tumor effects of RT involve the induction of single and double 
stranded DNA breaks with downstream apoptosis 40, important studies by several 
groups41,42 showed that RT has clear immunological effects, including the occasional 
induction of a systemic anti-tumor response, the so-called abscopal effect43. RT modulates 
several elements of the immune response; it promotes the secretion of pro-inflammatory 
cytokines such as IL-1 and IL-644; it enhances expression or release of damage-associated 
molecular patterns (DAMPs), including calreticulin, high mobility group box 1 (HMGB1) 
and ATP from affected tumor cells42,44,45; it increases MHC-I expression on tumor 
cells44,46; and it activates the stimulator of interferon genes (STING) pathway leading to 
type I interferon secretion47.  Together, these factors may lead to the maturation of 
dendritic cells, resulting in improved cross-presentation of tumor antigens and subsequent 
antigen-specific CD8 T cell responses34,42. 
Despite these multiple pro-inflammatory effects, the abscopal effect is clinically 
rare - suggesting that RT may also exert immunosuppressive effects, or amplify pre-
existing suppressive components of the tumor microenvironment (TME)5,48. The pro-
tumor microenvironment incorporates numerous mechanisms by which tumors evade 
host anti-tumor immune responses: for instance, RT has been correlated with increased 
levels of TGF-β49, a pluripotent cytokine which generally suppresses immune responses50. 
Another evasion method involves regulatory T cells (Treg), which play an important role 
in suppressing immune responses and are of clinical relevance20. Accordingly, Treg 
depletion has been shown to enhance CD8 T cell activity and limit tumor growth in animal 
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models26, and treatments targeting these cells are in various stages of clinical 
development51. However, the effects of RT on suppressive immune cells, especially Treg, 
have not been fully elucidated. Several reports suggest an increase of Treg post-radiation, 
both in animals and humans34,52-55, but whether radiotherapy may render tumor-
infiltrating Treg (TIL-Treg) both phenotypically and/or functionally more suppressive, 
has yet to be determined.  
To test the hypothesis that stereotactic radiotherapy increases phenotypically and 
functionally suppressive TIL-Treg, we used the Small Animal Radiation Research 
Platform (SARRP), which directs CT-image-guided radiation to selectively target 
tumors35 and models stereotactic radiotherapy in human patients, thus enabling us to 
investigate the phenotype and functional ability of TIL-Treg.  We also evaluated several 
potential mechanisms underlying the observed post-RT Treg increase, including TGF-β 





Stereotactic radiation increases Treg in multiple tumor types 
We first sought to investigate whether the previously observed RT-mediated increase in 
intratumoral regulatory T cells (Treg) 34,52-55 was a general phenomenon, i.e. whether it 
occurred across multiple tumor types.  For these studies, we used the Small Animal 
Radiation Research Platform (SARRP)35 (Figure III- 1A). At the dose studied, RT 
suppressed B16/F10 (melanoma) tumor growth, but did not completely eradicate the 
tumors (Figure III- 1B). Similar trends were observed in the RENCA (kidney cancer) and 
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MC38 (colorectal cancer) models (Supplementary Figure III 1A, 1B). These effects were 
confirmed by a comprehensive profiling of the post-RT TME; which revealed additional 
changes in the immuno-biology of the TME involving CD4+ T cells, CD8+ T cells and 
myeloid cells (Supplementary Figure III- 2). In all three tumor types studied, RT 
significantly increased both the proportion (Figure III- 1D, 1E) and absolute numbers of 
Treg (Figure III- 1C and data not shown). This effect was local; no significant increases 
in Treg were observed in either the DLN or spleen in any of the three models examined 
(Supplementary Figure III- 3).  This increase in Treg was accompanied by an increase 
in Foxp3 levels as assayed by MFI (Figure III- 1F) and was verified by IHC (Figure III- 
1G).  In addition, the Treg increase was persistent and was still present two weeks after 
the administration of RT (Supplementary Figure III- 4). Taken together these data 
established a model to study Treg following RT. 
The Phenotype of Treg Post-RT is Consistent with Activation 
We next tested whether RT treated TIL-Treg developed a phenotype different from that 
observed in untreated tumors. For this, we focused on: CCR4, which has been associated 
with Treg trafficking56; the checkpoint molecule cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4)57; the transcription factor Helios (IKZF2), which is up-regulated with 
activation58-60; and 4-1BB (CD137), which also increases with T cell activation61.  As 
shown in Figure III- 2, in the B16/F10 model, CCR4 was not significantly altered post-
RT.  By contrast, CTLA-4, Helios and 4-1BB expression were all significantly up-
regulated post-RT, potentially consistent with a more activated Treg phenotype.  Similar 
trends were noted in the RENCA and MC38 models (Supplementary Figure III 5 and 6). 
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Supporting a local immunological role for RT, none of these 4 markers were significantly 
altered in either the DLN or the spleen of RT-treated mice (Supplementary Figure III 7 
and 8). We also quantified expression of these markers in the non-Treg CD4 T cells 
(Tconv) and found that in both the B16 and RENCA models, 4-1BB and CTLA-4 were 
induced post-RT on T conv as well; this was not observed in the MC38 model 
(Supplementary Figure III 9-11). In none of the 3 models was 4-1BB significantly induced 
on CD8 post-RT (Supplementary Figure III- 12).  
 
 
TIL-Treg Retain Suppressive Function Post-RT 
Based on their increased expression of CTLA-457 and Helios58-60, we queried whether 
TIL-Treg demonstrated increased suppressive function after RT. To investigate the 
suppressive capabilities of post-RT Treg, we conducted micro-suppression assays36.  
Briefly, GFP-labeled TIL-Treg were sorted from Foxp3 reporter mice (B6.129(Cg)-
Foxp3tm3(DTR/GFP)Ayr/J ), which express GFP under the Foxp3 promoter19. As shown in 
Figure III- 3, we found that TIL-Treg from irradiated mice (RT TIL-Treg) were more 
suppressive than those from non-irradiated tumors (Control TIL-Treg) or un-manipulated 
spleens at low Treg:Tresponder ratios, but that at a higher ratio the three populations were 
functionally indistinguishable (Figure III- 3A and 3B).  Collectively, these data show 
that the post-RT Treg from TILs are indeed functional and demonstrate enhanced 





RT-Induced Expansion of TIL-Treg is Not TGF-β Dependent 
Given the well-described influence of TGF-β on Treg induction62, we next investigated 
whether the post-RT Treg expansion observed above was dependent on TGF-β signaling. 
To test this hypothesis, we treated B16/F10 tumor-bearing mice with Galunisertib 
(LY2157299), a small molecule TGFβR1 kinase inhibitor that nearly completely 
abrogates TGF-β signaling63-65. To optimize potential treatment effects, we began 
treatment with daily oral gavage (every 12 hours) one day prior to RT (Figure III- 4A).  
As expected, treatment with Galunisertib did not significantly alter tumor outgrowth, 
independent of the presence or absence of RT (Figure III- 4B). Interestingly, blockade of 
TGF-β did not significantly abrogate the RT-induced TIL-Treg increase as compared to 
the vehicle-treated control groups (Figure III- 4C). Neither the proportion of Foxp3+ cells 
(Figure III- 4D) nor the absolute numbers (Figure III- 4E) decreased, suggesting the post-
RT TIL-Treg increase was not strongly dependent on TGF-β in this model. In addition, 
the overall composition of the T cell infiltrate in these aggressive B16/F10 tumors was 
not significantly affected by Galunisertib; there was no significant difference in total CD3, 
CD4 or CD8 proportions (Supplementary Figure III- 13). We also tested whether RT was 
associated with increased levels of TGF-β1 or β2.  As shown in Supplementary Figure 
III- 14, levels of both TGF-β molecules increased as tumors progressed, but significant 
differences were not observed between irradiated and non-irradiated tumors.   
 
RT-Induced Expansion of TIL-Treg is Not IL-33 Dependent 
Since recent data suggest the possibility of an increase in IL-33 levels after RT66, we next 
tested whether this cytokine might be responsible for the increment of TIL-Treg after RT 
treatment.  To investigate this hypothesis, we quantified IL-33 levels in B16/F10 tumors 
post RT. As show in in Figure III- 5A, IL-33 levels increase after RT, consistent with 
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previous data.  Therefore, we treated mice with a neutralizing anti-ST2 (IL-33R) 
antibody37, starting one day prior to RT (Figure III- 5B). Anti-ST2 treatment did not 
significantly affect tumor outgrowth (Figure III- 5C). In addition, the blockade of ST2 
did not significantly abrogate the post-RT TIL-Treg increase (Figure III 5D-F). 
Furthermore, there was minimal expression of ST2 (IL-33R) on intra-tumoral Treg and 
that expression is not increased by RT (Supplementary Figure III- 15). Taken together, 
these data suggest that, in this model, the post-RT Treg increase is most likely not 
dependent on either TGF-β or IL-33. 
Radiation enhances the proliferation of TIL-Treg 
We next tested whether the observed increase in TIL-Treg post RT was due to Treg 
migration into tumors as opposed to being driven by intratumoral proliferation of pre-
existing TIL-Treg. To perform these studies, we treated B16/F10-bearing mice with 
Fingolimod (FTY720), a blocker of the sphingosine 1-phosphate receptor 1; this drug 
effectively blocks T cell egress from lymphoid organs38,67.  As in the studies above, 
treatment was initiated one day prior to radiation (Figure III- 6A). As expected, 
administration of Fingolimod resulted in an approximately 75-80% decrease in peripheral 
blood lymphocytes counts from baseline (Supplementary Figure III- 16), and did not 
significantly affect tumor growth (Figure III- 6B). Fingolimod seemed to slightly blunt 
the TIL-Treg increase, but did not abrogate it completely (Figure III- 6C and 6D). 
Accordingly, we next investigated the proliferation of intratumoral Treg via Ki-67 
staining. RT consistently increased Treg proliferation within tumors both in the presence 
or absence of Fingolimod (Figure III 6E - 6G).  Of note, although post-RT proliferation 
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occurred to some extent in all T cell subsets, the increased proliferation of Treg was more 
pronounced than in the other subsets examined (Figure III- 6G). Of note, nearly all T cell 
subtypes in the tumor had increased proliferation post-RT, however, TIL-Treg have a 
higher baseline proliferation rate, making the ratio of Treg increase post-RT (Figure III- 
6 H, I) 
 
DISCUSSIONS 
Radiation therapy is a mainstay of cancer treatment and is broadly used across a 
spectrum of tumor types.  The basic mechanism of action of RT is to induce single and 
double-stranded DNA breaks, leading to apoptotic cell death, with tumor cells being 
preferentially affected 40,68.  However, accumulating evidence suggests that RT has clear 
immunological effects as well - including the occasional induction of a systemic anti-
tumor response, the so-called abscopal effect 41,42.  
Here we found an increased frequency of Treg in the TME of several tumor types 
(B16/F10, RENCA and MC38) following treatment with RT (Figure III- 1). The 
consistency across these disparate tumor types (using two separate mouse strains) is in 
agreement with prior results34,52-55. 
We investigated Treg-specific expression of several molecules post-RT: 
chemokine receptor CCR456, the checkpoint molecules CTLA-457 and 4-1BB61, and the 
transcription factor (Helios). Post RT, we found increased expression of CTLA-4, 4-1BB 
and Helios, consistent with an activated/ suppressive phenotype (Figure III- 2). Based on 
the increased expression of CTLA-457 and Helios58-60 observed in RT treated TIL-Treg, 
we next sought to investigate whether these cells demonstrated greater suppressive 
capability than their non-treated counterparts. Interestingly, Treg from RT treated tumors 
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not only retained their ability to suppress effector cell proliferation, but were in fact more 
suppressive at a low Treg: Tresponder ratios (Figure III- 3). To our knowledge, these data 
represent the first report of a micro-suppression assay using sorted TIL-Treg from mice 
treated with stereotactic RT; and may be important in understanding a potential counter-
balance to RT-induced immune activation 42,69-71.  
We interrogated several potential molecular mechanisms underlying the RT 
mediated increase in the frequency of TIL-Treg. A primary consideration was TGF-β for 
three reasons. First, TGF-β induces the expression of Foxp3, the master transcription 
factor for Treg72, in traditionally CD4+Foxp3- effector CD4 T-cells62,73. Second, RT has 
been shown to correlate with increased TGF-β expression49. Lastly, several prior studies 
suggest synergistic anti-tumor effects when RT is combined with TGF-β blockade74-76. 
Thus, we blocked TGF-β signaling using the small molecule inhibitor Galunisertib 
(LY2157299), which prevents phosphorylation of SMAD2 by inhibiting TGF-β receptor 
I kinase 63-65.  Surprisingly, we were not able to influence the TIL-Treg increase induced 
by RT with TGF-β blockade (Figure III- 4). These results are not consistent with previous 
studies by Wu et al. 77 in which TGF-β blockade was shown to mitigate the TIL-Treg 
increase after irradiation in a murine prostate cancer model. The reasons for the 
discrepancy between these results are not obvious, but may include differences in the 
models used, or in agents used - prior studies used intraperitoneal delivery of a 
neutralizing antibody against TGF-β1 or transfection with TGF-β1 shRNA, whilst we 
orally administered a small-molecule inhibitor currently under investigation in a number 
of clinical trials64.    
In addition, we investigated IL-33, a cytokine that has recently been described 
to be important in Treg expansion in several models78-80.  Consistent with a previous 
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report66, we found that RT increased the levels of IL-33 in the TME.  We thus blocked 
IL-33-IL-33R (ST2) signaling using antibodies against ST2 to test whether IL-33 might 
play a role in the observed increment of TIL-Treg post RT. IL-33 blockade did not 
abrogate the TIL-Treg increase after irradiation (Figure III- 5), leaving the precise 
molecules or signaling pathways driving Treg expansion in our models a matter for 
ongoing investigation. We also found that the post-RT TME includes a number of 
dynamic changes in the expression of multiple immunological transcripts involving 
diverse immune cell subsets. This not only highlights the complexity and dynamics of the 
TME, but also suggests additional avenues for intervention (Supplementary Figure III- 
2).  Some of the effects of RT appeared to transcend cell subtype; for example, we noted 
increased proliferation of CD4, CD8 and Treg post-RT.  By contrast, some cell surface 
proteins were differentially affected, with 4-1BB expression up-regulated post-RT on 
Treg but not on CD8 T cells.  These data highlight the complex effects of RT on the 
immune components of TME. 
We next sought to determine whether the observed increase was due to Treg 
proliferation in situ, or due to an increased trafficking of peripheral Treg to the TME. For 
these studies, we used Fingolimod, a small-molecule S1P signaling inhibitor that largely 
blocks T cell emigration from lymph nodes. We hypothesized that if the RT TIL-Treg 
increase was due to an influx of new immune cells into irradiated tumors, then it would 
be blocked or at least significantly blunted by Fingolimod treatment.  In multiple 
iterations, the post-RT Treg increase appear to be blunted but not abrogated in the 
presence of this agent (Figure III- 6).  From a technical standpoint, Fingolimod treated 
mice displayed less infiltration when considering the density of T cells (ubiquitously 
across all immune cell types) in the TME, these low numbers may be a source of variation 
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in population frequencies. Therefore, it is formally possible that at least partially, 
trafficking of Treg may play a role in the increased Treg frequency in the TME, as 
suggested by an increased level of the CCR4 ligands: CCL17 and CCL22 in RT-treated 
tumors (Supplementary Figure III- 17).  Finally, we turned our attention to the 
possibility of Treg expansion/proliferation driving the post-RT increase of TIL-Treg. Of 
note, we found a consistent increase in TIL-Treg proliferation post-RT, suggesting that 
proliferation likely explains a significant fraction of the post-RT Treg increase. 
Interestingly, nearly all T cell subtypes in the tumor had increased proliferation post-RT, 
however, TIL-Treg have a higher baseline proliferation rate, making the ratio of Treg 
increase post-RT (Figure III- 6 H, I), leading to a potential suppressive counterbalance to 
the well-described stimulatory effects of RT42,69,70,81. And we did not see the difference in 
death rate between non-irradiated tumor-derived TIL versus irradiated tumor derived TIL 
(Supplementary Figure III- 18), which further support the roles of proliferation rather than 
the difference in cell death rate. 
Underlying mechanism for the above phenomenon has not been clear yet. One 
potential candidate could be IL-2, considering the global proliferation among T cell 
subsets post-RT, and the dependence of Treg on IL-2 for their survival and suppressive 
functions82,83. Although the IL-2 level in tumor lysate was not significantly different in 
protein level and transcription level between irradiated and non-irradiated tumors 
(Supplementary Figure III- 2, 17), kinetics of IL-2 secretion from immune cells, or the 
experiments in IL-2 knockout mice or with IL-2 blockade as well as a changes in signaling 
with phosphorylation of STAT5 will follow. In addition, origin of the Treg; whether they 
are thymic-derived or periphery-induced Treg, as well as novel molecules upregulated 
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post-RT for Treg-targeted immunotherapy (Supplementary Figure III- 19) are also worth 
investigating. 
Another important question would be whether the RT-induced Treg expansion 
was due to the primary impact of RT to Treg (i.e. radio-resistance of Treg) or the 
secondary impact from RT to the TME. The parallel adoptive transfer experiments where 
tumor-implanted RagKO mice (or Foxp3DTR mice depleted Treg with DT) are 
adoptively transferred with irradiated Treg or the tumors were irradiated and non-
irradiated Treg are adoptively transferred and see in which condition Treg would expand. 
As the nanostring data showed, complex and dynamic immunological changes occur in 
the TME; thus we cannot underestimate the impact of irradiated TME. But interestingly, 
TIL, especially TIL-Treg proliferate under RT and still survive; although typically 
proliferative cells are more sensitive to radiation induced cell death, suggesting there is a 
cell intrinsic mechanism especially for TIL-Treg to be radio-resistance. Along those lines, 
it is suggested that TIL-Treg has higher expression of cFLIP, anti-apoptotic molecule, 
making them resistant to FasL-induced cell death.84 Considering the known effect of RT 
to induce FASL expression on tumor cells (and could be stromal cell as well)42, it is 
possible that TIL-Treg, especially post-RT, have higher expression of cFLIP and counter 
act with the FASL induced cell death. Adoptive transfer experiment experiments using c-
FLIP KO/KD T cells or conditional KO mouse (especially temporal KO) of c-FLIP in 
Treg85 might help to elucidate the impact of this molecule. 
In addition, along the lines of migration and the secondary impact from TME, 
common lymphatic endothelial and vascular endothelial receptor 1 (CLEVER1) on blood 
endothelial cells (BEC) has been suggested to preferentially mediate Treg extravasation84, 
which might also explain the increased Treg population in the TME post-RT, if RT 
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increased the expression of CLEVER. Thus the impact of stromal cells in the TME cannot 
be underestimated as well.  
Furthermore, exploring other immune-suppressive cells post-RT, and relation to 
Treg would be also interesting area to explore further. It has been suggested that RT could 
also increase MDSCs in the TME86 (and Weichselbaum’s group personal conversation). 
Interestingly, our preliminary data from B6/F10 tumor-bearing mice showed the almost 
diminished population of LD-CD45+Ly6C+Ly6G+ population (“(Granurocytic) G-MDSC” 
population), leading to increased monocytic/granurocytic -MDSC ratio (M/G-MDSC 
ratio) (Supplementary Figure III- 20). Further characterization in different time points 
(especially early time points) or different types of tumors, and delineation of specific 
myeloid population (as the above population could include neutrophils), underlying 
mechanisms (different apoptosis ratio, for example), and how they could affect TIL-Treg 
are needed, but this data suggest that RT could modulate the population of MDSC (and 
myeloid cells) as well. 
The strengths of these studies include a well-defined, localized and consistent 
RT treatment regimen using the SARRP platform35, which we used to model single-dose 
stereotactic radiation.  In addition, we carefully controlled for tumor size at the time of 
treatment.  Potential limitations include the use of implanted tumor models, which may 
or may not accurately recapitulate the TME in human tumors, and that we did not 
thoroughly test other radiation doses or fractionation regimens. Thus, it is possible that 
our results may not translate to other treatment regimens. Nevertheless, the results 
obtained here are consistent with prior work34,52-55 showing that RT may have Treg 
inducing affects which may need to be considered in clinical regimens that combine RT 
with immunotherapy.  In addition, we clearly documented that the post-RT intratumoral 
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Treg have suppressive function, providing a rationale for regimens combining Treg-
targeted strategies with RT.  Indeed, such combination regiments may be required to 
optimize the immune effects of RT in patients.  
FUTURE PLANS 
(I am writing RO1 grant draft with Dr. Drake based on this project.) 
The following are the future plans of the project. Mainly three-folds. 
(1) To determine the mechanism(s) by which RT induces Treg expansion in the tumor
microenvironment. 
1.1 Test the hypothesis that TIL-Treg are more radio-resistant 
To test this hypothesis, we will perform clonogenic survival assay to compare the 
sensitivity to RT of Treg, especially TIL-Treg with other T cell subsets (conventional T 
cells (Tconv)). If we proved TIL-Treg are more radioresistant, we will determine the 
mechanisms; whether the radioresistant is dependent on cell cycle or apoptosis, and 
whether they are linked to DNA damage response. 
1.2 Determine the mechanism by which RT triggers proliferation (and activation) of TIL-
Treg 
It is hypothesized that enhanced IL-2 signaling post-RT will trigger the proliferation of 
TIL-Treg. To test the hypothesis, we will evaluate the enhancement of IL-2 signaling via 
phosphor-flow and immunoblot of downstream target of IL-2R, including STAT5, as well 
as directly evaluate the impact of IL-2 in vivo by combination therapy of IL-2 blockade 
with RT and transgenic mice model where we conditionally and inducibly knockout the 
IL-2R signaling in Foxp3+Treg. 
(2) To optimize RT combined with Treg modulating immunotherapy in physiologically
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relevant animal models 
2-1 RT increases the expression of immune-checkpoint molecules on TIL-Treg 
(CTLA4, 41-BB, CCR8) and targeting the molecules in combination with RT results in 
better anti-tumor immunity 
2-2 RT dose and fractionation optimization will affect TIL-Treg expansion 
(3) To test the hypothesis that RT increases Treg infiltration and/or alters phenotype in
patients receiving palliative SBRT with biopsy accessible lesions 
3-1 RT increases Treg expansion in the tumors of cancer patients (renal cell
carcinoma, prostate cancer, and bladder cancer) 
3-2 Comprehensively profile TME pre- and post- RT lesions
(1) To determine the mechanism(s) by which RT induces Treg expansion in the tumor
microenvironment. 
1.1 Test the hypothesis that TIL-Treg are more radio-resistan 
Our preliminary data suggest that TIL-Treg proliferate robustly post-RT and maintain 
their suppressive function87. This appears counter-intuitive because as a general trend, 
more proliferative cells tend to be more vulnerable to the RT-induced cell death, which 
does not necessarily seem to apply for TIL-Treg. This led us to the hypothesis is that Treg 
in the TME are radioresistant. Separately, we will also determine the mechanism by which 
RT triggers the proliferation (and activation) of TIL-Treg. 
To test the hypothesis, we will conduct in vitro clonogenic survival assay both in mouse 
and human cells. For mouse, we will isolate Foxp3+Treg and CD4 and CD8 T 
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conventional cells from spleen, draining lymph node and tumor of tumor-implanted or 
control YFP-Foxp3-CRE mice, cultured in FBS-containing media in round 96 well plate 
supplemented with IL-2. We will irradiate them (0-20 Gy) and evaluate the cell death 
rate) 7 days post-RT. For translational relevance, we will do the same setting of 
experiment evaluating the radioresistance in vitro by using human PBMC (Leukopak) 
derived Treg (CD4+CD25+CD27-) as well as other non-Treg T conventional cells (CD4, 
CD8) subsets.  
We will use the Curve and DER (dose-enhancement ratio (DER) at 10% cell survival) as 
readout. We expect to observe that Treg, especially TIL-Treg are more radioresistant, with 
the shifter curve toward upright and DER greated than 1 compared with other Tconv 
subsets. If this was true, the hypothesis will be confirmed and this would offer significant 
insight in to one of the mechanism for patients refractory to RT. Then, we will further 
pursue to determine if those cells respond differently to RT based on cell cycle (like 
“Mitotic Catastrophie” like the ways tumor cells die by radiologists) by G2 block (to test 
check point function different) and by examining the markers of cell cycle (to test if there 
was any difference in distribution in cell cycles (i.e. less cells are in G2/S (radiosensitive) 
but in G0 (radioresistant) suggesting radioresistant), by the expression of CDKs by 
Westernblot, flowcytometry. We will also examine if Treg die more by apoptosis (just like 
“lymphocytes’ way of death by RT by radiologists) using Live/Dead, 7-AAD, annexin-V, 
caspase-1,8 by Western, flowcytometry as readouts. The potential pitfall could be other 
types of cell death than mitotic catastrophie and apoptosis might be involved. If we did 
not see the difference, we could further expand our search into other types of cell death 
such as necrosis, pyroptosis, autophagy. 
We will also determine if this is related to DNA damage or test the hypothesis that 
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Treg are radio-resistant because they have better DNA damage response (DDR). To 
test the DNA damage, by flow cytometry and IF, we will stain gamma-H2AX. TO test 
if Treg has better recovery from DNA damage (better DNA damage response (DDR)), 
we will perform Comet assay and test the Markers of NHEJ (DNA PKCs, XRCC4 by 
Western blot). We will expand our investigation into cGAS-STING-type I IFN 
pathway as well. 
 If DNA damage (1-3) was true, we could also look into the effect of TGF-b and 
adenosine, suggested to dampen radiosensitivity of tumor cells75 and protect the 
normal tissue cells88, respectively.  
To test the relevance in vivo, we could use double reporter mice from Rudensky group89 
and we could generate Foxp3eGFPCD4 Cre-ERT2 R26Y mice so that tamoxifen 
administration can label all T cells and can distinguish Treg vs Tconv by GFP 
expression. We could also make Ebi3 CRE to make it CD8 specific. We will monitor 
the survival of the YFP-labelled Treg (as well as other YFP-labelled Tconv in second 
model) by cell numbers, ratio of the cell death, as well as examine the pro- and anti-
cell death markers listed in Table I over the time course using flow-cytometry and 
immunoblots. We are expecting to see the high survival and increased anti-apoptotic 
protein expression for YFP+Treg from irradiated tumors. 
We are also considering the possibility of Treg becoming  radio-resistant by the 
irradiated TME-derived factors. We hypothesized that Treg are radioresistant because 
they make adenonosine which protects them from RT and (oxidative) stress. TME is 
rich in  generally immunosuppressive adenosine, and evidence suggest the expression 
of A2AR CD39, 73 on Treg make them suppressive and Treg secretion of adenosine 
further contribute to the immune suppression in the TME. RT increase release of ATP 
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as a DAMP, the source of adenosine4, and the adenosine pathway blockade revealed 
anti-tumor in multiple tumor types, suggesting the potential efficacy of combination 
therapy of RT and adenosine blockade pathway, which might involve TIL-Treg. Treg-
derived Adenosine could counteract ROS to make the cells radioresistant (Treg protect 
HSC as niche in bone marrow, and adenosine from Treg stop cell cycle in G0 in HSC 
in bone marrow. (Hirata, Fujisaki et al unpublished) These data led us to hypothesize 
that Treg protect themselves from RT-induced cell death by counteracting ROS by 
adenosine pathway. We will be testing this hypothesis using pharmacological approach 
and genetic approach both in vitro and in vivo. To determine the impact of RT-induced 
adenosine pathway on TIL-Treg survival and dissect the contribution from (1) the 
production of adenosine by Treg and (2) the sensitivity/downstream signaling of 
adenosine receptor on Treg (A2AR), we will use treatment both of blocking antibody 
and small molecule antagonists of adenosine-producing enzyme (CD73 and CD39) and 
A2AR in combination with radiation and measure the survival rate, and pro- and anti- 
cell death markers, both in vitro and in vivo, using pharmacological (mAb, small 
molecule inhibitors against CD37, A2AR etc.). For transgenic model approach, we will 
cross A2AR floxed mice (Adora2atm1Dyj ; available from Jackson might need extra 
breeding to B6 as B6;129-Adora2atm1Dyj/J) and CD39 floxed mice (with Foxp3YFP-CRE 
mice to generate Treg specific knockout of A2AR (receptor of adenosine) and CD39 
(enzyme required for conversion of ATP into adenosine). We will use Foxp3 YFP-CRE 
mice as control.  For in vitro experiment, we will isolate CD39 (or A2AR) KO Treg 
from CD39fl/flFoxp3YFP-CRE mice (or A2ARfl/flFoxp3YFP-CRE mice) or WT Treg isolated 
from Foxp3YFP-CRE mice from tumor, draining lymph node and spleen of tumor(MC38, 
B16/F10)-bearing mice, and culture followed by irradiation in the method used in 1.1 
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and evaluate the survival, death rate, proliferation and pro/anti-cell death markers 
expression listed in Table 1, as well as suppressive function of CD39/A2AR KO Treg 
and compared with the WT control, by immunoblot and flowcytometry and in vitro 
suppression assay. We expect to observe the impaired survival of CD39/A2AR KO 
Treg upon irradiation, especially in TIL-Treg. For in vivo approach, we will implant 
tumors (B16/F10, MC38) in CD39fl/fl Foxp3YFP-CRE and A2AR fl/fl Foxp3YFP-CRE mice, 
and irradiate the tumors with SARRP RT and YFP+Foxp3+ TIL-Treg will be evaluated 
for the survival, apoptosis markers over the time. We will use Foxp3YFP-CRE mice as a 
WT control and Foxp3-DTR mice as negative control for the experiment. We will 
evaluate the tumor growth with measuring tumor volumes and weight, as well as the 
survival and markers of TIL-Treg as well as in vitro suppression assay. We expect to 
observe the impaired survival of CD39/A2AR KO Treg upon irradiation, especially in 
TIL-Treg leading to the better tumor control and enhanced CD8 response measured by 
intracellular staining of IFN-g, TNF-a, GzmB (and Elispot assay).  
To further investigate and delineate the impact of Treg-derived adenosine itself (using 
CD39 floxed and adenosine signaling (using A2AR floxed) on TIL-Treg’s radio-
resistance, we will generate heterozygous CD39 fl/fl Foxp3Cre-YFP/DTR-GFP female mice 
(and A2AR fl/fl Foxp3Cre-YFP/DTR-GFP), where 50% of Tregs have a Cre-mediated deletion 
of CD39 (A2AR), are marked with YFP, whereas the other 50% express DTR-GFP and 
are WT Treg, as they carry the CD39 fl/fl allele (or A2AR allele) but not Foxp3Cre-YFP 
within the same mouse without the administration of DT (as Foxp3 in on X 
chromosome and only one allele will be expressed due to the random inactivation). 
And we will use Foxp3 CRE-YFP/CRE-YFP mice and CD39 fl/fl Foxp3 CRE-YFP/CRE-YFP mice 
(or A2AR fl/fl Foxp3 CRE-YFP/CRE-YFP) as controls90,91. The strength of this genetic model 
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is that we could compare the WT and KO Treg population within the same mouse, so 
WT Treg can serve as an internal control. We will subcutaneously implant 
immunogenic MC38 or less-immunogenic B16/F10 to these mice, and irradiate the 
tumors with SARRP, and follow up the survival, apoptosis markers of YFP+CD39KO 
Treg versus GFP+CD39WT Treg (or A2AR KO vs WT TIL-Treg) in the tumor over 
time just as above. If the adenosine from Treg was important for the survival of TIL-
Treg post-RT, not only YFP+CD39 KO Treg will more sensitive to RT-induced cell 
death but also GFP+CD39KO Treg will become more sensitive to RT-induced cell 
death due to the less availability of adenosine provided from irradiated tumor-derived 
Treg, whereas if the adenosine signaling on Treg make them radioresistance, 
GFP+A2AR WT Treg will outnumber YFP+A2AR KO Treg and show increased 
survial and anti-apoptotic molecule expression in post-RT TME. 
Other than adenosine, another TME derived factors potentially make Treg 
radioresistant and /or make them proliferate could be TGF-beta. It is well-known that 
RT-increase TGF-b and TGF-b induce Treg. Although our data using Galunisertib 
(LY2157299 monohydrate), small-molecule TGFbR1 kinase inhibitor did not abrogate 
Treg expansion post-RT87, it is still possible that TGF-b impacts TIL-Treg in TGFbR1-
independent mechanism including the “non-classical” pathways of TGF-b other than 
TGF-bR/Smad3/4 pathway, including LRP1. To explore the possibilities, we will use 
other TGF-b blockade approach and genetic mouse model. For pharmacological 
approach, we will use pan-TGF-beta blockade antibody (1D11 (a pan-isoform, TGFβ-
neutralizing mouse mAb that binds only to active TGFβ) 74in combination with RT. We 
will treat the tumor-bearing mice with 1D11 or isotype control starting from a day prior 
to the RT every other day (200 ug) and evaluate the impact of TGF-b neutralization to 
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RT-induced Treg (expansion and the pro- and anti-apoptotic markers (such as caspase-
1/3, or Bcl-2 respectively) of TIL-Treg and other conventional T cells. We will also 
conduct the same experiment using LRP inhibitors. For genetic approach, we will 
generate Treg-specific knockout of Smad4 mice by crossing Foxp3YFP-CRE with Smad4 
fl/fl mice (Smad4tm2.1Cxd/J)). We will implant B16/F10 and MC38 in 
Smad4fl/flFoxp3YFP-CRE mice followed by SARRP radiation, and evaluate the Treg 
increase post-RT. We will also generate Smad4 fl/fl Foxp3Cre-YFP/DTR-GFP and conduct the 
similar experiment as mentioned in adenosine section. 
(2) To optimize RT combined with Treg modulating immunotherapy in physiologically
relevant animal models 
Our previous study showed that RT expand TIL-Treg with activated and functionally 
suppressive phenotype post-RT92, which gave a rationale to develop TIL-Treg targeted 
immunotherapy in combination with RT to maximize the anti-tumor response. In 
addition, although single fraction irradiation gives great insights and opportunity for 
well-controlled experiments with clinical relevance in SBRT, recent study also 
suggests the that changing dose and fractionation schemes could result in different 
impact to trigger innate and adaptive anti-tumor immune response including c-GAS-
STING pathway followed by DNA damage, leading to the activation of type I IFN 
pathway93, supporting modulation of dose and fractionation scheme will be another 
parameter to optimize the efficacy of the treatment. Therefore, in order to optimize the 
RT combined with Treg modulating immunotherapy, we will test the different 
immunotherapy targeting relatively specifically expressed on TIL-Treg, and also test 
the different dose and fractionation scheme, separately and in combination in vivo, 
using transgenic mouse models for different tumor types with phygiological relevance 
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as well as xenograft tumor models. 
2-1: RT increases the expression of immune-checkpoint molecules on TIL-Treg
(CTLA4, 41-BB, CCR8 (CCR4)) and targeting the molecules in combination with RT
results in better anti-tumor immunity.
(And DUSPs and RGSs described in Chapter IV might fit into this.) 
Earlier studies suggest the augmented anti-tumor effect with Treg-depletion in 
combination with RT26,34. One of the challenges of Treg-targeted immunotherapy is 
the side effects of autoimmunity especially if the depletion of Treg was systemic, 
supporting the importance of selectively targeting TIL-Treg. Recently, using RNAseq 
from different cancer patients (prostate, RCC, bladder, glioblastoma), we have 
identified some molecules relatively specifically and highly expressed in TIL-Treg 
(Nirschl, Muroyama, Drake at al (refer Chapter IV for details)), which was also 
validated in protein levels, including CTLA-4, 4-1BB and CCR8, which are expressed 
on the surface of TIL-Treg thus more targetable by mAb and clinically applicable. We 
showed that CTLA4 and 41-BB expression in TIL-Treg increased post-RT92. Using 
the same approach, we will test the CCR8 expression on TIL-Treg post-RT in vivo.)Our 
preliminary data showed, using the monoclonal antibody against CTLA4 whose 
isotype is IgG2a, in which FcR-dependent ADCC are relatively strong compared to 
the other isotypes, serving as depleting antibody of the targets, that selective TIL-Treg 
depleting aCTLA4 Ab in combination with RT eradicated the established tumors in 
more than 80 % of the MC38-bearing mice, with better survival and long- lasting 
immune response with increased CD8 effector/Treg ratio, and overcome second tumor 
challenge, compared with single treatment (RT alone, aCTLA4 alone) and untreated 
group. (Marsiscano, …Muroyama, …Drake at al (in submission)) Using this model, 
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we will also expand our search in combination therapy of other targets, 4-1BB and 
CCR8 in vivo. We will use MC38 (-OVA), B16/F10 (-OVA), RENCA (-HA), and 4T1 
(-HA) subcutaneous models as well. Furthermore, with the collabolation, we will test 
the antibody in physiologically relevant transgenic mouse models of other tumor types; 
Melanoma (Bosenburg mice), Prostate cancer, Pancreatic cancer; KPC model, Gastric 
cancer, as well as human cell line or human tumor xenograft implanted in humanized 
mice. For the treatment groups, we will have untreated (isotype control as negative 
control), RT (+ isotype control), mAb alone, and use Foxp3-DTR mice treated with 
DT for genetic depletion of Treg, insetead of mAb as “positive control”. We expect the 
see that combination therapy of TIL-Treg targeted immunotherapy with RT showed 
improved survival, tumor eradication with anti-tumor immune response. (If we did not 
observe the significant and improved anti-tumor response, we will further looking into 
other TIL-Treg targeting molecules found in our RNAseq data., including CD177.) 
2-2: RT dose and fractionation optimization will affect TIL-Treg expansion
Recent study showed that the dose of RT and fractionation scheme can significantly 
impact the immunogenicity of tumor cells. One study suggest that radiation dose above 
12-18 Gy induce Trex1 to degrade cytosolic DNA, which activate STING pathway and
type I IFN flowed by Batf3+ DC enhancing CD8 effector response, leading high dose 
RT less immunogenic to induce abscopal effect. And hypofractionation (8 Gy x3) will 
help to accumulate the cytosolic DNA and further make the tumor immunogenic 93(The 
dose we have been using, 10 Gy, fits into “immunogenic” range inducing dsDNA 
without significant induction of Trex1.) However, the impact of dose and 
hypofractionation on TIL-Treg induction post-RT has not been fully elucidated. We 
hypothesized that TIL-Treg will still increase post-RT in different doses and 
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fractionation scheme, but the most “immunogenic” regimen could increase the TIL-
Treg most because those tumors would by highly “Hot” or “T-cell inflamed” tumors, 
and if so the combination with TIL-Treg targeted immunotherapy above would 
significantly augment the anti-tumor response. (Test abscopal effect too??) To test the 
impact of dose, we will first irradiate tumor-bearing mice (B16/F10, MC38) by 
different dose of RT (0 – 30 Gy) by single fraction, and determine the number, ratio, 
phenotype (activation marker CTLA4, 41BB, Helios), proliferation (Ki-67) and 
function (in vitro suppression assay) of Treg (especially TIL-Treg), as well as effector 
CD8 (and CD8/Treg) by flow cytometry (and IHC) and tumor volume and survival. 
We will determine the dose of best anti-tumor response. Next, using that dose or 8 Gy 
as Demaria’s paper, we will compare the impact of fractionation on the expansion of 
TIL-Treg, by using 8,10 Gy x1, 8 Gy x3, 20 Gy x1, 30 Gy x1 using the same readout 
as above. We expect to observe the increase of suppressive Treg even in different dose 
and fractionation scheme. But expect to see the most increased and suppressive TIL-
Treg in “immunogenic” regimen. If this worked, we will further pursue to test the 
combination therapy of that RT scheme with TIL-Treg depletion strategies developed 
above to see the additive and synergistic anti-tumor effect.  
(3) To test the hypothesis that RT increased Treg infiltration and/or alters phenotype in
patients receiving palliative SBRT with biopsy accessible lesions 
3-1: RT increases Treg expansion in the tumors of cancer patients (renal cell 
carcinoma, prostate cancer, and bladder cancer) 
My study showed above in multiple preclinical mouse models that RT increased Treg 
infiltration and make them into more suppressive phenotype23. And numbers of 
clinical reports support the improved anti-tumor response in combination therapy of 
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radiation and ipilimumab. We hypothesized that RT induce the increase and 
activated/suppressive phenotype of TIL-Treg in patients received SBRT. To test the 
hypothesis, we will obtain biopsy samples of pre-RT tumor and post-RT tumors from 
RCC, prostate cancer and bladder cancer patients, with written informed consent. We 
will use both flow cytometry and IHC with Foxp3 staining for the evaluation of TIL-
Treg. For flowcytometry experiments, the fresh tumors will be digested using Human 
tumor dissociation kit and gentle MACS dissociator (Milteniyl), single cell suspention 
will be stained for L/D, CD3, CD4, CD8, CD25, CD127, Foxp3 and markers of 
interest (CTLA4, 41-BB and Helios), Ki-67 for the analysis of the numbers, ratio, 
survival, and expression of the markers of “activated Treg” of TIL-Treg (LD-
CD3+CD4+CD25+CD127-Foxp3+) population. We will use corresponding 
peripheral blood T cell populations as control. For IHC staining, the samples fill be 
FFPE-fixed and stained for Foxp3 expression with pathologist’s evaluation. (If 
possible) biopsy samples from non-tumor and non-irradiated surrounding tissues will 
be used as a control. We expect to see that, as the same as preclinical model, TIL-Treg 
will increased in post-RT tumors with increased expression of CTLA4, 41BB, Helios 
and Ki-67, which will validate the clinical relevance of the impact of RT on TIL-Treg. 
One of the technical challenges of this approach will be the paucity of cell components 
obtained from small and limited biopsy samples. If we encounter the pitfalls, we will 
use an alternative approach of single cell RNAseq or Nanostring immune assay for the 
evaluation of transcriptional signature of the whole TME using the whole obtained 
tumor samples and de-convolute and evaluate the Treg-gene signatures using 
computational approach. Another pitfall of this approach will be the potential sample 
bias, as a nature of  biopsy and of the intratumoral heterogeneity of the immune 
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signature in the TME depending on the regions within the tumor. To minimize the 
sample bias and to obtain the representative tumor samples, we will be using CT/MRI-
guided targeted biopsy and target multiple regions of tumor parenchyma, and analyze 
the samples from multiple locations. 
3-2:  Comprehensively profile TME pre- and post- RT lesions 
My study shown that RT induce dynamic and complex immunological changes in the 
tumormicroenvironment in preclinical mouse model using Nanostring.23 To evaluate the 
immune profile of the TME in HUMAN patients, using the biopsy samples pre- and post-
RT as described above, we will characterize both 3-2-1: immune profiling and 3-2-2: 
immune cell subsets location in the tumor, taking into the heterogeneity of the TME into 
account. 
3-2-1: We will perform single cell RNA sequenencing. We will sort out the immune cell 
population from patients samples as a bulk and conduct scRNAseq using 10x platform, 
and de-convult immune signature with computational approach. 
3-2-2: To test the distribution of immune cells, especially CD8 effector cells and 
phenotypically suppressive TIL-Treg in the TME, we will conduct Poly chromatic IF with 
immune monitoring core. Potenaial pitfall could be small sample size. Alternative 
approach could be using surgery case taking RT to reduce tumor size pre-operation 








Radiotherapy (RT) enhances innate and adaptive anti-tumor immunity; however, the 
effects of radiation on suppressive immune cells, such as regulatory T cells (Treg), in the 
tumor microenvironment (TME) have not been fully elucidated. Although previous 
reports suggest an increased Treg infiltration post-radiation, whether these Treg are 
functionally suppressive has not been determined. To test the hypothesis that RT enhances 
the suppressive function of Treg in the TME, we selectively irradiated implanted tumors 
using the Small Animal Radiation Research Platform (SARRP), which models 
stereotactic radiotherapy in human patients – followed by flow-cytometric and functional 
analyses of tumor-infiltrating lymphocytes (TILs). Our data showed that RT significantly 
increased tumor-infiltrating Treg (TIL-Treg), which had higher expression of CTLA-4, 
4-1BB, and Helios as compared to non-irradiated tumors. This observation held true
across several tumor models (B16/F10, RENCA, and MC38). Notably, we found that 
post-RT, TIL-Treg had equal or improved suppressive capacity compared to non-
irradiated tumors. Our data also indicated that post-RT, Treg proliferate more robustly 
than other T cell subsets (CD3, CD4, and CD8) in the TME. In addition, the post-RT Treg 
expansion occurred when T cell migration was inhibited using Fingolimod - suggesting 
that the increased Treg frequency was likely due to preferential proliferation of 
intratumoral Treg post-radiation. Our data also suggested that post-irradiation Treg 
expansion was independent of TGF-β and IL-33. Collectively, these data demonstrate that 
RT increases phenotypically and functionally suppressive Treg in the TME, and provide 
a rationale for treatment regimens that combine RT with Treg-targeting agents to 
maximize anti-tumor efficacy. 
49
“Intended to be blank”
50
CHAPTER IV: NOVEL TREG-ASSOCIATED 
TARGETS FROM HUMAN TUMOR 
INFILTRATING LYMPHOCYTES (TIL) 
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INTRODUCTION 
Accumulating evidence suggests that Treg are the negative force against tumor immunity. 
In pre-clinical models, depletion of Treg results in better tumor control with enhancement 
of effector T cell response25-27. In humans, Treg infiltration in tumor and low CD8/Treg 
ratio are reported to correlate with poor prognosis in patients in some types of 
cancers20,28,29, and the depletion of Treg by low dose cyclophosphamide have shown 
better anti-tumor response30,31 , and the treatments with anti-CTLA4 antibody, which at 
least partly exerts its anti-tumor effect via Treg depletion through ADCC, have shown 
clinical response in different types of tumors32,33. Despite the potential importance of Treg 
in the tumor progression and resistance to anti-tumor immunity, and its importance as a 
therapeutic target, the exact properties of TIL-Treg, and the determinant molecule for the 
function of Treg in human tumor, have not been clear yet. This has been a challenging 
question as numbers of molecules expressed on TIL-Treg, which have activated 
phenotype20,94,95, and are overlapped with activated effector T cells, and targeting those 
molecules could potentially affect activated T effector cells, which are important for anti-
tumor effect, as well. In addition, even the molecules were expressed on Treg, systemic 
depletion of Treg will lead to auto-immunity thus targeting molecules selectively 
expressed on TIL-Treg will be important20. Therefore, finding out the targetable 
molecules selectively expressed on TIL-Treg or effectively modulate TIL-Treg functions, 
especially in human, are of vital importance with clinical significance. Here, we have 
performed RNA sequencing (RNAseq) of the peripheral blood mononuclear cells 
(PBMCs) and TILs from prostate cancer, glioblastoma and renal cell carcinoma patients 
(and urothelial carcinoma (bladder cancer) in progress), and conducted extensive 
profiling of TIL-expressing molecules. Of note, we have included activated conventional 
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T cells in PBMC as control as well as naïve T cells, which enable us to distinguish the 
markers for activation and the markers of TIL-Treg, and to profile the kinetics of 
molecules upon activation. From the dataset, we have identified novel molecular targets 
for human TIL-Treg, including DUSP1, DUSP4, RGS1 and RGS16, which are highly 
expressed on TIL-Treg and showed unique expression patterns. Notably, DUSP1 and 
DUSP4 showed reciprocal expression pattern, where the expression of the former was 
downregulated upon activation. Expression of the molecules was confirmed by qPCR 
both in mouse and human, and we are further characterizing their roles in Treg in vitro 
and in vivo.  
RESULTS 
RNA sequencing data revealed genes highly expressed in TIL-Treg 
We sorted out the following populations; from PBMC, we isolated naïve CD4 cells 
(CD4+CD45RA+CCR7+CD27+CD28+), Treg (CD4+CD25+CD127+), naïve CD8 cells 
(CD8+CD45RA+CD27+CD28+), and antigen-experienced CD8 cells (CD8+CD45RO+), 
and from tumor infiltrating cells, we isolated Treg and antigen-experienced CD8 cells 
(Supplementary Figure IV-1). We also prepared activated CD4/CD8 population, by 
stimulating naïve CD4/CD8 with anti-CD3 and CD28 in vitro. We included these 
activated populations as control as well, since large population of Treg-associated genes 
are also upregulated in activated T cells17,96. Thus, we expected these control groups will 
help identifying the genes selectively expressed in TIL-Treg or help finding out the genes 
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with unique expression patterns. 
To identify the candidate target genes, we looked into the expression patterns of the genes 
which are highly expressed in TIL-Treg, compared to the three different controls, namely 
PBMC CD4 naïve cells, PBMC CD4 activated cells, and PBMC Treg (Figure IV-1A, B, 
C, respectively). We used FPKM (Fragments Per Kilobase Million) as readouts. 
The expression patterns of the genes from prostate cancer RNAseq are shown in Figure 
IV-1 and Figure IV-2. CCR4, which is a chemokine receptor expressed in activated Treg,
which recruit Treg in the TME via chemokine ligands CCL17 and CCL2295 are relatively 
selectively highly expressed in Treg and TIL-Treg, consistent with the previous finding. 
(Figure IV-2A) (As shown in Figure 2 in Chapter III, we confirmed the expression of 
CCR4 in mouse tumors as well.) CCR6, another chemokine receptor for CCL20, is 
relatively selectively expressed in TIL-Treg.  (Figure IV-2B) (Along the lines of 
chemokine receptors, we and others have shown the selective expression of CCR8, 
CD177 and IL1R2 in TIL-Treg (Thomas Nirschl, Yuki Muroyama, Charles Drake et al. 
unpublished data)97,98. METRNL (Meteorin Like, Glial Cell Differentiation Regulator), 
which is not-well characterized gene associated with beige fat and improving glucose 
intolerance99-102, is highly expressed in TIL, which could be a potential target for tumor 
metabolism (Figure IV-2C). RGS16, a negative regulator for G-protein coupled receptor 
were associated with activation (Figure IV-2D). For fucosyltransferase 7 and 9 (FUT7 
and FUT9), which mediate the systhesis of CD15s (sialyl Lewis x), which is reported to 
define suppressive Treg in human103, expression level was low, but show a trend for 
higher expression in more aggressive prostate cancer (Figure IV-2E, F). Solute carrier 
family 1 member 2 (SLC1A2) is a glutamate transporter reported to be expressed in 
central nervous system104 were highly expressed in TIL (Figure IV-2G), suggestive for 
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the potential role in modulating tumor metabolism. Fibrinogen-like protein2 (FGL2), 
reported to be downstream suppressive effector molecule of TIGIT105,106 was also highly 
expressed in TILs (Figure IV-2H). 
Among them, the interesting expression patterns were seen in DUSP1, DUSP4 and RGS1. 
(Figure IV-3) 
Unique expression pattern of DUSP1, and reciprocal pattern with DUSP4 
DUSP1 (dual specificity phosphatase 1), showed an unique expression pattern; DUSP1 
was expressed in naïve CD4 T cells, and down-regulated upon activation despite of high 
expression in Treg and TIL-Treg. (Figure IV-3). 
Whereas DUSP4 showed the reciprocal pattern with DUSP1; which is upregulated 
activation, highly expressed in Treg. This expression pattern held true across different 
types of tumors analyzed; prostate cancer (Figure IV-3A), glioblastoma (Figure IV-3B) 
and renal cell carcinoma (Figure IV-3C), supportive for the expression pattern being 
global phenomenon. To verify the expression pattern shown in RNAseq, we conducted 
the qPCR both in human and mice, with designated time course (from 12 hours to 72 
hours post activation) and saw the similar pattern: DUSP1 showed down regulation upon 
activation in time-dependent manner both in conventional T cells and in Treg. And 
DUSP4 showed the reciprocal pattern. (Figure IV-3 D, and Supplementary Figure IV-2A, 
B (with preliminary tumor-derived sample data)). Next, we examined whether this pattern 
would hold true for the corresponding mouse T cell population, whether we could develop 
the mice model. Using GFP-Foxp3 mice, we isolated naïve CD4 T cells 
(CD4+CD62L+CD44-), naïve CD8 T cells (CD8+CD62L+CD44-), Treg (CD4+Foxp3+), 
antigen-experienced CD8 T cells (CD9+CD62L-CD44+) (Supplementary Figure IV-3). In 
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vitro activation was performed with the stimulation with CD3 and CD28 just like in 
human experiments. We saw the similar expression pattern of DUSP1 and DUSP4 in 
mouse as well (Figure IV-3E, and Supplementary Figure IV-3 B-G (with preliminary TIL 
and DLN data)).  
This reciprocal expression pattern of DUSP1 and DUSP4 led me the hypothesis that these 
two molecules reciprocally regulate Treg activation/function.  
In addition, DUSP1 and DUSP4 showed similar expression pattern in CD8 cells; where 
DUSP1 expression decreased upon activation, high expression in antigen-experienced 
cells, especially in tumor, and DUSP4 showed reciprocal patterns (Figure IV-4, 
Supplementary Figure IV-3 B-G (with preliminary TIL and DLN data)), suggestive for 
the multifold action of those molecules in TIL. 
High RGS1 expression in TIL 
Another gene which is one of the top genes highly expressed in TIL-Treg was RGS1 
(Figure IV-1), a negative regulator of G-protein coupled receptors107,108. RGS1 was 
selectively highly expressed in TIL (TIL-Treg and TIL-Ag-experienced cells) in prostate 
cancer, glioblastoma and renal cell carcinoma RNAseq (Figure IV-5 A-C). We also 
confirmed its expression pattern by qPCR both in human and mice as described above 
(Figure IV-5 D, E). 
Generation of selective knockout mice for Dusp1 and Rgs1 
To further characterize the role of DUSP1, DUSP4 and RGS1 in vivo, we generated the 
floxed mice for DUSP1 and generating RGS1. The schemes are shown in Figure IV-6A 
and B, respectively. We are crossing these mice to Foxp3-Cre and CD4-Cre mice to 
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generate Treg or T cell specific knockout of those genes, and characterize their role in 
vivo. We are planning to test in vivo suppression assay, tumor models and autoimmune 
models including colitis and EAE to test the genes function in Treg in vivo. We will make 
additional knockout mice depending on the phenotype observed (including double 
reporter mice (Foxp3-GFP-Cre BAC transgenic mice were crossed to Rosa26-loxP-Stop-
loxP-YFP (R26-YFP) reporter mice) or temporal knockout (with ERT) or depletion of 
Treg (Foxp3-DTR) to test the effect of those genes for stability of Treg.  
The impact of DUSP1, DUSP4 and RGS1 on suppressive function of Treg in 
vitro 
To test the role of the selected genes on suppressive function of Treg in vitro, we are 
performing knocking down those genese via siRNA in human PBMS, followed by in vitro 
suppression assay. (Supplementary Figure IV-4A) 
The siRNA transfection with electroporation knocked down the Foxp3 expression 
(positive-control) for up to 72 hours (Supplementary Figure IV-4B) and downregulated 
of Rgs1 RNA expression (and Helios) but not for Dusp1 and Dusp4 (Supplementary 
Figure IV-4C), where further optimization is required. We are also considering other 
approach including CRISPR-Cas9 knockout, and lipid-free transfection reagent. We are 
also working on improving the suppression assay using human PBMC. (primary data 
shown in Supplementary Figure IV-4D, E). 
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DISCUSSIONS: 
Here we identified novel genes associated with human tumor-infiltrating Treg (TIL-Treg), 
including DUSP1, DUSP4 and RGS1 in different types of tumors; prostate cancer, renal 
cell carcinoma, and glioblastoma (urothelial carcinoma in progress). Those genes are 
highly expressed in TIL-Treg and could be a potential therapeutic target.  
Notably, expression of DUSP1 is downregulated upon activation via stimulation through 
CD3 and CD28, both in T conventional cells and in Treg. This is of special interest as 
many Treg-associated genes are also upregulated upon T cell activations, including 
CTLA-417,22,96, but the expression pattern of DUSP1 was actually the opposite; down-
regulated upon activation despite of high expression in Treg. Furthermore, the expression 
pattern of DUSP1 and DUSP4 was reciprocal; DUSP1 expression was observed in naïve 
T conventional cell, was down-regulated upon activation in time-dependent manner and 
was high in Treg and down-regulated upon activation of Treg, and its expression was 
especially high in TIL-Treg. On the other hand, DUSP4 expression was up-regulated upon 
activation, its expression was high in Treg and further up-regulated upon activation, and 
high expression in TIL-Treg was observed. In addition, DUSP1 and DUSP4 are very 
homologous, they are 78% homologous and form the closest cluster in alignment tree of 
DUSP proteins109, suggestive of the common ancestor molecule. These data drove me a 
hypothesis that DUSP1 and DUSP4 were derived from a common ancestor molecule, and 
with some mutations, they diverged into different molecules which reciprocally modulate 
Treg activation and function. 
To test this hypothesis of reciprocal regulations, we will be working on double 
knockdown/knockdown in vitro to see the Treg function, titration experiments by knock-
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in, and making double knockout mouse by crossing DUSP1, DUSP4 floxed mice to Treg 
specific, T cell specific CRE mice. 
Dual specificity phosphatases (DUSPs) are also known as MAPK phosphatases (MKPs), 
which are the primary phosphatases responsible for dephosphorylation/deactivation of 
MAPKs in vivo109-111. As the name suggest, they dephosphorylate both threonine/serine 
and tyrosine. Their targets are p38, c-jun N-terminal kinase (JNK), and ERK, but the 
target specificity depends on the cell types. For example, in macrophage, DUSPs are 
reported to dephosphorylate p38 and JNK upon activation, but had little effect on ERK, 
whereas in T cells, DUSPs primary regulate JNK activities, perhaps ERK but not 
p38109,110.  
In relation to immune system, DUSP1 has been known as a negative regulator of innate 
immunity. DUSP1 knockout macrophage have higher secretion of pro-inflammatory 
cytokines upon TLR stimulation, and DUSP1 knockout mice are more susceptible to 
systemic inflammation such as sepsis upon LPS 112,113. Less is known for the roles of 
DUSP1 in adaptive immunity. Global DUSP1 knockout mice revealed normal 
thymocytes development, and CD4/CD8 ratio were comparable to wild type (WT)109,114. 
And in dendritic cells, DUSP1 is shown to reciprocally regulate Th1/17 differentiation of 
T cells in cytokine dependent manner and downregulating iTreg generation via reduced 
TGF-beta2 secretion from dendritic cells (DC)115. However, the role of DUSP1 in Treg, 
especially in the context of tumor microenvironment and its interactions with other 
DUSPs have not been elucidated. 
Of translational relevance, in addition to immune cells, DUSP1 is highly expressed in 
prostate, breast, gastric, renal cancer, and non-small cell lung cancer (NSCLC)109, and has 
been shown to inhibit cisplatin-induced apoptosis in NSCLC cells, osteosarcoma cells, 
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and breast cancer cells in JNK dependent manner. Indeed, numbers of DUSP inhibitors 
have been under development116-118 as anti-tumor drug to augment the therapeutic effects 
of chemotherapy. Thus, if DUSP1 is necessary for suppressive function in Treg, DUSP1 
inhibition could not only blocking suppressive Treg but also help inducing tumor cell 
apoptosis, which could result in synergistic anti-tumor effects. 
In addition, DUSPs are known to be induced by glucocorticosteroid, and are suggested to 
play roles in anti-inflammatory effects of steroids, although involvement of multiple 
DUSPs with compensatory roles each others have been suggested as well109. Therefore, 
in future direction, relation to the signaling of glucocorticoid-induced TNFR-related 
protein (GITR), or TNFRSF18, might be of interest as well, considering the high 
expression and potential roles of GITR in Treg119. (Experiments comparing 
transcriptional profiles of GITR positive and negative were underway (data not shown)). 
DUSP4 shares some common DUSP features mentioned above. Phenotype of global 
knockout mice varies among different deletion strategies. One study suggests that, ERK 
signaling, which has been suggested to be a primary target for DUSP4, in Treg/Tconv was 
comparable to WT120, and so does the generation of induced Treg (iTreg). However, 
DUSP4 has been suggested to be one of the few genes with Treg-specific epigenetically 
active landscape (H3K27ac), both in mouse and human, suggestive for Treg lineage 
identifier96 . Nevertheless, the exact functional role of DUSP4 in Treg especially in the 
context of the TME, as well as the interaction with other DUSPs including DUSP1 have 
not been elucidated yet. 
Therefore, understanding the role of DUSP1 and DUSP4 in Treg, especially in the context 
of the TME, and the reciprocal regulation with molecular mechanisms will not only offer 
the unique opportunity to understand the TIL-Treg function as well as to develop the 
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novel therapeutic strategies for cancer immunotherapy as well as autoimmune disease as 
the opposite side of the coin. 
Once the reciprocal regulation between DUSP1 and DUSP4 has been established in vitro 
and in vivo, we will further look into the underlying mechanisms. One potential 
mechanism for reciprocal regulation, suggested from the previous literature could be the 
negative feedback of DUSP4 to inhibit ERK1/2, which is one of the inducer of DUSP1 
transcription shown in macrophage121,122. 
RGS1 is a negative regulator of G-protein coupled receptor (GPCR), including 
chemokine receptors, serving as a GTPase-activating protein (GAP)107. In T cells, RGS1 
is known to downregulate the signaling of CXCR4-CXCL12 in bone marrow, and CCR7-
CCL19 in lymph node108. Thus, it is possible that RGS1 might help retaining T cell/Treg 
in tissue such as gut. And considering the high expression in TIL from our RNAseq data, 
we could speculate that RGS1 in TIL might help them stay in tumor, keeping Treg 
infiltration. RGS1 expression in tumor is either increased or decreased depending on 
tumor types123. For example, RGS1 upregulation is reported in esophageal 
adenocarcinoma, renal cell carcinoma (RCC), Head and neck squamous cell carcinoma 
(SCC), Brain tumors, Melanoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular 
lymphoma (FL), and downregulation is reported in bladder cancer and Chronic 
Lymphocytic Leukemia (CLL). Global RGS1 knockout mice revealed a normal 
distribution of CD4 and CD8 expression on thymocytes, but decreased B cell migration 
to CXCL12, 13124. However, its role in Treg especially in the context of the TME has not 
been elucidated. To test that, like DUSP1/4, in vitro suppression assay via 
knockdown/knockout of the RGS1 gene is under progress, and we generated RGS1 floxed 
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mice to be able to perform experiments in Treg, T cell specific knock out mice by crossing 
the mice with the specific CRE-expressing mice.  
Nevertheless, this research will elucidate the roles of novel targets associated with human 
TIL-Treg, which will help understanding their roles in different disease settings, such as 
tumors and autoimmunity, and will help developing the Treg-targeted immunotherapy to 
maximize anti-tumor effect, or contrary, to protect against autoimmunity. 
SUMMARY 
Treg has been implicated as negative force and protective for tumor growth. Numbers of 
preclinical studies suggest that depletion of Treg have better outcome for tumors, and 
clinical data with anti-CTLA4 blockade, which is known to block or deplete Treg have 
support this notion25-27,29,32. However, what is exactly the determinant molecule for Treg 
in human TIL, which has much more clinical relevance and of large therapeutic target, 
has not been clear. 
Here, using RNAseq data from prostate cancer, renal cell carcinoma, and glioblastoma 
(and urothelial carcinoma) patients, we have identified DUSP1, DUSP4 and RGS1 as 
well as other genes which are highly expressed in human TIL-Treg and have unique 
expression pattern; especially DUSP1 expression is down-regulated upon T cell 
activation, contrary to majority of Treg-associated genes whose expression will increase 
upon activation17, and shows reciprocal expression pattern with DUSP4. These gene 
expression was confirmed by q-PCR both in human and mice and in vitro functional 
studies and in vivo characterization by knockout mice are underway. In addition, I 
hypothesized that, from the reciprocal expression pattern and homology, DUSP1 and 
DUSP4 are reciprocally regulating Treg activation and function, and RGS1 plays a 
62
regulatory role in TIL. 
Further in vitro and in vivo studies will follow to delineate the roles and interactions of 
those genes in TIL-Treg, and will give new frontiers for Treg-targeted immunotherapies. 
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FIGURE LEGENDS FOR CHAPTER I 
Figure I-1: Balance between anti-tumor immunity and immuno-suppression 
in the tumor microenvironment (TME) 
Figure I-2: Timeline for basic and clinical development of PD-1/PD-L1 targeted 
cancer immunotherapy 
Upper timeline: Pre-clinical studies, Lower / magnified timeline: FDA approvals    
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FIGURE LEGENDS FOR CHAPTER III 
Figure III-1: Stereotactic radiotherapy increases Treg in tumors. 
(A) Experimental design. 5x105 B16/F10, 1.5x106 MC38 or 3x105 RENCA cells were
implanted subcutaneously (s.c.) to the flank of wild-type C57BL/6J mice (in B16/F10 or 
MC38 experiments) or Balb/c mice (in RENCA experiment), respectively on day 0. Mice 
received 10 Gy of stereotactic radiotherapy (RT) via SARRP on day 7 (B16/F10), day 16 
(RENCA), day 10 (MC38), respectively. Tumors, draining lymph nodes (DLN), and 
spleens were harvested 7 days after the radiation. (B) Tumor growth curves of B16/F10-
bearing mice as in (A). Non-irradiated tumors (control) in black line and irradiated tumors 
(RT) in red line, respectively. (C) The absolute number of TIL-Treg per gram tumor 
weight in B16/F10 model. (D-F) Representative flow plots (D) and quantitative bar graph 
of % Foxp3+ cells (E) and MFI of Foxp3 (F) in CD4+ cells from TILs. N = 7-15 per group, 
repeated at least 4x. (G) Immunohistochemistry of Foxp3 in tumors (B16/F10, RENCA, 
MC38), 20X and 40X magnification as indicated.  Foxp3+ cells are stained red in 
B16/F10 (due to the brown pigment in melanoma), and brown in RENCA and MC38 
tumors.  Error bars represent SEM, ***: p < 0.001, **: p < 0.01, *: p < 0.05, determined 
by two-way ANOVA (B) or unpaired Student’s t-test (C, E and F). 
Figure III-2: Stereotactic radiotherapy increases the activation/suppression 
markers of tumor-infiltrating Treg (TIL-Treg).  
(A, B) Representative flow plots (A) and quantitative scatterplot (B) depicting of the 
percentages of CCR4+, CTLA4+, 4-1BB+ or Helios+ TIL-Treg, from day 14 B16/F10 
tumor-bearing mice. N= 8 per group, repeated 3x. Error bars represent SEM, ***: p < 
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0.001, **: p < 0.01, *: p < 0.05, determined by unpaired Student’s t-test (B). 
Figure III-3: Radiated tumor-infiltrating Treg (TIL-Treg) are functionally 
suppressive.  
(A) Representative figure of the in vitro suppression assay. Tresponder cells were gated
based on the CD45.1 congenically marked and their proliferation was analyzed based on 
the dilution of CTV dye. Solid lines show the conditions with Spleen Treg (black line), 
non-irradiated Control TIL-Treg (blue line), and RT TIL-Treg (red line); filled green 
histograms shows the Tresponder only condition.  (B) Quantitative plots represent 
percent suppression at the indicated Treg:T responder ratio. A representative experiment 
of a total of three independent replicates is shown. (N = 2-3 per group, repeated 3x.) 
Figure III-4: The effect of TGF-β on post-RT increase of Treg in tumor. 
(A) Experimental design. C57BL/6 mice were injected subcutaneously with 5x105
B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a dose of 
300 mg/kg/day Galunisertib (LY2157299) or vehicle via oral gavage every 12 hours, 
starting a day before RT. Tumors, DLNs and spleens were harvested on day 14. (B) Tumor 
growth curves of vehicle versus Galunisertib treated mice (dashed lines versus real line 
respectively), with or without radiation (black line or red line, respectively). (C) 
Representative flow plot of TIL-Treg. (D, E) Quantitative scatter plots of the % Foxp3+ 
cells of tumor-infiltrating CD4+ cells (D) and the absolute number of TIL-Treg per gram 
tumor weight (E) in Galunisertib treated versus vehicle treated group. (B) N = 5-6 per 
group, repeated x2. (D, E) show pooled data from two experiments. Error bars represent 
SEM, ***: p < 0.001, **: p < 0.01, *: p < 0.05, determined by two-way ANOVA (B), and 
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unpaired Student’s t-test (D, E). 
Figure III- 5: The effect of IL-33 on post-RT increase of Treg in tumor. 
(A) The time course of IL-33 level in tumor lysates from different time points (1, 6, 24,
48, 72 hours and 7 days post RT) measured by ELISA. N = 5 per group. (B) Experimental 
design. C57BL/6 mice were injected subcutaneously with 5x105 B16/F10 cells on day 0. 
Mice received 10 Gy of RT on day 7. Mice received a dose of 200 μg/mouse anti-ST2 
antibody (Anti-ST2 Ab) or vehicle intraperitoneally (i.p.) every 3 days, starting one day 
before RT. Tumors, DLNs and spleens were harvested on day 14. (C) Tumor growth 
curves of vehicle control (dashed-line) versus anti-ST2 Ab-treated mice (solid line), with 
or without radiation (black or red, respectively). (D) Representative flow plot of TIL-Treg. 
(E, F) Quantitative scatter plots of % Foxp3+ cells of tumor-infiltrating CD4+ cells (E), 
and the absolute number of TIL-Treg per gram tumor weight (F) in anti-ST2 Ab-treated 
versus vehicle-treated group. N = 5 per group, repeated x2. Error bars represent SEM, 
***: p < 0.001, **: p < 0.01, *: p < 0.05, determined by two-way ANOVA (A, C), and 
unpaired Student’s t-test (E, F). 
Figure III- 6: Stereotactic radiation enhances preferential Treg proliferation in the 
tumor microenvironment (TME).  
(A) Experimental design. C57BL/6 mice were injected subcutaneously with 5x105
B16/F10 cells on day 0. Mice received 10 Gy of RT on day 7. Mice received a dose of 25 
μg Fingolimod (FTY720) or PBS containing DMSO as control via oral gavage on day 6, 
9, 12. Peripheral blood was collected for monitoring lymphocyte counts. Tumors, DLNs 
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and spleens were harvested on day 14. (B) Tumor growth curves of vehicle versus 
FTY720-treated mice (dashed line versus solid line respectively), with or without 
radiation (black or red line respectively). (C) Representative flow plot of TIL-Treg (CD4+ 
Foxp3+). (D) Absolute number Treg per gram tumor weight in FTY720-treated versus 
vehicle treated group.  (E, F) Representative flow plot (E) and quantitative scatter plot 
(F) of tumor-infiltrating Ki-67+ Treg (CD4+ Foxp3+ cells). (G) Quantitative scatter plot
of Ki-67 expression in tumor-infiltrating CD3+, CD4+, CD8+ T cells and Treg. (H) Fold 
change of Ki-67 expression of irradiated TIL to compared with that of non-irradiated TIL. 
(I) Quantitative scatter plot of Ki-67 expression in tumor-infiltrating CD3+, CD4+, CD8+
T cells and Treg from non-irradiated tumors. N = 9-10 per group, repeated x2. (D) shows 
pooled data from two experiments. Error bars represent SEM, ***: p < 0.001, **: p < 
0.01, *: p < 0.05, determined by Two-way ANOVA (B), unpaired Student’s t-test (D, F-
I).  
Supplementary Figure Legends: 
Supplementary Figure III- 1: Radiotherapy suppresses tumor growth. 
(A, B) Tumor volume curves of RENCA (A) and MC38 (B) bearing mice. Non-irradiated 
tumors in black line and irradiated tumors in red line, respectively. N = 5-15 per group, 
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repeated at least 4x. Error bars represent SEM, ***: p < 0.001, **: p < 0.01, *: p < 0.05, 
determined by unpaired t-test at the day of harvest (A, B).  
Supplementary Figure III- 2: Characterization of the TME of B16/F10 tumors post-
RT.  
Heatmaps of RNA expression of genes associated with immune cell subsets by 
NanoString assay. RNAs were extracted from the tumors on day 14 B16/F10 tumor-
bearing mice (7 days post RT). N= 4-5 per group.  
Supplementary Figure III- 3: Stereotactic radiation does not change Treg in 
draining lymph nodes nor in spleens of treated mice.  
(A, C) Representative flow plots of Treg from DLN (A) and spleen (C) from B16/F10, 
RENCA, or MC38 bearing mice. (B, D) Bar graph of % Foxp3+ cells in CD4+ cells from 
DLN (B) and spleen (D). N = 7 - 14 per group, repeated at least 4x. Error bars represent 
SEM, ***: p < 0.001, **: p < 0.01, *: p < 0.05.  
Supplementary Figure III- 4: Persistently Increased Treg Post-RT.  
Representative flow plots (A) and quantitative scatterplot (B) depicting of the percentages 
of Foxp3+ cells in CD4+ cells from TILs, from day 21 (14 days post-RT) B16/F10 tumor-
bearing mice. N= 7-9 per group, repeated 2x. Error bars represent SEM, *: p < 0.05, 
determined by unpaired Student’s t-test (B).  
Supplementary Figure III- 5: Stereotactic radiation increases the suppressive 
markers of Treg in the RENCA tumor model.  
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(A, B) Representative flow plots (A) and quantitative scatterplot (B) depicting the 
percentages of CCR4+, CTLA-4+, 4-1BB+ or Helios+ TIL-Treg, from day 23 RENCA-
bearing mice. N = 7 per group, repeated 3x. Error bars represent SEM, ***: p < 0.001, 
**: p < 0.01, *: p < 0.05, determined by unpaired Student’s t-test (B).  
Supplementary Figure III- 6: Stereotactic radiation increases the suppressive 
markers of Treg in the MC38 tumor model.  
(A, B) Representative flow plots (A) and quantitative scatterplot (B) depicting the 
percentages of CCR4+, CTLA4+, 4-1BB+ or Helios+ TIL-Treg, from day 17 MC38-
bearing mice. N = 14 per group, repeated x2. Error bars represent SEM, ***: p < 0.001, 
**: p < 0.01, *: p < 0.05, determined by unpaired Student’s t-test (B).  
Supplementary Figure III- 7: Stereotactic radiation does not change the expression 
of the suppressive markers of Treg in DLNs.  
(A, B) Representative flow plots (A) and quantitative scatterplot (B) depicting the 
percentages of CCR4+, CTLA4+, 4-1BB+ or Helios+ Treg, from DLNs of day 14 B16/F10-
bearing mice. N = 8 per group, repeated 3x. Error bars represent SEM, ***: p < 0.001, 
**: p < 0.01, *: p < 0.05, determined by unpaired Student’s t-test (B).  
Supplementary Figure III- 8: Stereotactic radiation does not change the expression 
of the suppressive markers of Treg in spleens.  
(A, B) Representative flow plots (A) and quantitative scatterplot (B) depicting of the 
percentages of CCR4+, CTLA4+, 4-1BB+ or Helios+ Treg, from spleens of day 14 
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B16/F10-bearing mice. N = 8 per group, repeated 3x. Error bars represent SEM, ***: p < 
0.001, **: p < 0.01, *: p < 0.05, determined by unpaired Student’s t-test (B).  
Supplementary Figure III- 9: Expression of the selected markers of TIL-
CD4+Foxp3- cells (Tconv) in the B16/F10 model. 
 (A, B) Representative flow plots (A) and quantitative scatterplot (B) depicting the 
percentages of CCR4+, CTLA-4+, 4-1BB+ or Helios+ TIL-CD4+Foxp3- cells, from day 14 
B16/F10-bearing mice. N = 8 per group, repeated 3x. Error bars represent SEM, ***: p < 
0.001, **: p < 0.01, *: p < 0.05, determined by unpaired Student’s t-test (B).  
Supplementary Figure III- 10: Expression of the selected markers of TIL-
CD4+Foxp3- cells (Tconv) in the RENCA model. 
 (A, B) Representative flow plots (A) and quantitative scatterplot (B) depicting the 
percentages of CCR4+, CTLA-4+, 4-1BB+ or Helios+ TIL-CD4+Foxp3- cells, from day 23 
RENCA-bearing mice. N = 9 per group, repeated 3x. Error bars represent SEM, ***: p < 
0.001, **: p < 0.01, *: p < 0.05, determined by unpaired Student’s t-test (B).  
Supplementary Figure III- 11: Expression of the selected markers of TIL-
CD4+Foxp3- cells (Tconv) in the MC38 model. 
 (A, B) Representative flow plots (A) and quantitative scatterplot (B) depicting the 
percentages of CCR4+, CTLA-4+, 4-1BB+ or Helios+ TIL-CD4+Foxp3- cells, from day 17 
MC38-bearing mice. N = 14 per group, repeated 2x. Error bars represent SEM, ***: p < 
0.001, **: p < 0.01, *: p < 0.05, determined by unpaired Student’s t-test (B).  
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Supplementary Figure III- 12: Expression of 4-1BB on TIL-CD8+ cells. 
(A, B) Representative flow plots (A) and quantitative scatterplot (B) depicting the 
percentages of 4-1BB+TIL-CD8+ cells, from day 14 B16/F10-bearing mice, day 23 
RENCA-bearing mice and day 17 MC38-bearing mice. N = 8-14 per group, repeated 2-
3x. Error bars represent SEM, ***: p < 0.001, **: p < 0.01, *: p < 0.05, determined by 
unpaired Student’s t-test (B).  
Supplementary Figure III- 13: The effect of TGF-β blockade on different T cell 
subsets. 
(A-C) The absolute numbers of tumor-infiltrating CD3+ (A), CD4+ (B) and CD8+ (C) cells 
per gram tumor weight from vehicle treated and Galunisertib treated groups, with or 
without radiation, from day 14 B16/F10-bearing mice are shown. N = 5 per group, 
repeated x2. Error bars represent SEM, ***: p < 0.001, **: p < 0.01, *: p < 0.05, 
determined by unpaired Student’s t-test (A-C).  
Supplementary Figure III- 14: TGF-β expression in the tumor microenvironment. 
(A-C) Female Balb/c mice were subcutaneously implanted with 3x105 RENCA cells and 
received 10 Gy RT as previously described. Tumor lysates were collected at different time 
points post RT and the intratumoral levels of TGF-β1 and TGF-β2 were analyzed by 
Luminex assay. N = 4 - 5 per group. (A) Heatmap of log2 (fold change of radiated tumor 
chemokine levels compared to those of non-radiated control tumors). (B, C) Time courses 
of TGF-β1 and TGF-β2. TGF-β levels were normalized to tumor protein concentration. 
N = 4 - 5 per group. Error bars represent SEM, ***: p < 0.001, **: p < 0.01, *: p < 0.05, 
determined two-way ANOVA (B, C).  
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Supplementary Figure III- 15: ST2 expression on splenic and tumor infiltrating Treg. 
(A) Representative flow plots depicting the percentages of ST2+ Treg from spleen and
tumor of day 14 B16/F10-bearing mice, repeated x2. 
Supplementary Figure III- 16: The effect of Fingolimod (FTY720) on peripheral 
blood lymphocytes counts. 
Peripheral blood samples were collected from tail veins on day 5, 7, 11, and 13. 
Sequestration of peripheral lymphocytes was monitored using Hemavet whole blood cell 
counter. Time course of the concentration of lymphocytes (A) and ratio to the baseline 
lymphocyte counts (B), vehicle versus FTY720-treated mice (dashed line versus solid 
line respectively), with or without radiation (black or red line respectively).  
Supplementary Figure III- 17: Chemokine/cytokine expression of a selected panel in 
the tumor microenvironment post-radiation.  
(A, B) Female Balb/c mice were subcutaneously implanted with 3x10⁵ RENCA cells and 
received 10 Gy RT as previously described. Tumor lysates were collected at different time 
points post RT and chemokine/cytokine (IL-2) levels were analyzed by Luminex assay. 
(A) Heatmap of log2 (fold change of radiated tumor chemokine levels compared to those
of non-radiated control tumors). (B) Time courses of selected chemokines/cytokines. 
Chemokine/cytokine level were normalized to tumor protein concentration. Non-
irradiated tumors are represented by a black line, and irradiated tumors are represented 
by a red line, respectively. N = 4 - 5 per group. Error bars represent SEM, ***: p < 0.001, 
**: p < 0.01, *: p < 0.05, determined two-way ANOVA (B).  
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Supplementary Figure III- 18: RT does not increase the cell death of TIL-Treg. 
Quantitative scatterplot depicting the percentages of Live/Dead negative (“alive”) TIL-
Treg (A), as well as other T cell subsets (B) from day 14 B16/F10-bearing mice. N = 7 
per group, repeated 3x. Error bars represent SEM, p-value determined by unpaired 
Student’s t-test (A, B). 
Supplementary Figure III- 19: Differentially expressed molecules post-RT TME of 
B16/F10 tumors.  
(A) PCA analysis and (B) Volcano plot of RNA expression of genes associated with RT
by NanoString assay. RNAs were extracted from the tumors on day 14 B16/F10 tumor-
bearing mice (7 days post RT). N= 4-5 per group. 
Supplementary Figure III- 20: RT decreased G-MDSC (PMN-MDSC) population in 
B16/F10 tumor. 
(A, B) Representative flow plots (gated on LD-CD45+ cells) (A) and quantitative 
scatterplot (B) depicting of the percentages of Ly6C+Ly6G+ (“G-MDSC”) cells, 
Ly6C+Ly6G+ (“M-MDSC”) cells, and ratio of M/G-MDSC cells, from day 14 B16/F10 
tumor-bearing mice. N= 7-8 per group. Error bars represent SEM, ***: p < 0.001, **: p < 
0.01, *: p < 0.05, determined by unpaired Student’s t-test 
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Supplementary Figure III- 1
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Supplementary Figure III- 2
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Supplementary Figure III- 4
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Supplementary Figure III- 5
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Supplementary Figure III- 6
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Supplementary Figure III- 7
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Supplementary Figure III- 9
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Supplementary Figure III- 10
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Supplementary Figure III- 11
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Supplementary Figure III- III-15: ST2 expression on splenic and tumor 
infiltrating Treg
Supplementary Figure III- 15
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Supplementary Figure III- 18
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Supplementary Figure III- 19: Differentially expressed molecules post-RT 
TME of B16/F10 tumors.
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Supplementary Figure III- 19
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Supplementary Figure III- 20: RT decreases G-MDSC (PMN-MDSC) 























































































































































Supplementary Figure III- 20
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FIGURE LEGENDS FOR CHAPTER IV 
Figure IV-1: Volcano Plots for TIL Treg vs PBMC Controls. 
Volcano plot comparing the log odds versus log FC (fold-change) for genes from TIL-
Treg relative to PBMC CD4 naïve cells (A), PBMC CD4 activated cells (B), and PBMC 
Treg. 
Figure IV-2: Genes differently expressed in TIL-Treg from prostate cancer patients 
RNAseq data 
Scatter plots of RNA expressions represented by FPKM for CCR4, CCR6, METRNL, 
RGS16, FUT7, FUT9, SLC1A2, FGL2 from RNAseq of prostate cancer patients. N = 
12 (High Grade: Gleason Grade ≥ 4+3; N=6, Low Grade: Gleason Grade ≤ 4+3; 
N=6). ***: p < 0.001, **: p < 0.01, *: p < 0.05, determined by unpaired Student’s t-test. 
Figure IV-3: Downregulation of DUSP1 upon activation despite its high expression 
in Treg, with the reciprocal expression pattern with DUSP4. 
(A-C) Scatter plots of RNA expressions represented by FPKM for DUSP1 and DUSP4 
expression in CD4 T cells from RNAseq of multiple tumor types; (A) prostate cancer, 
(B) glioblastoma, and (C) renal cell carcinoma. N = 12, 8, 6, respectively. (D-E)
Confirmation by qPCR for DUSP1 and DUSP4 in human and mouse; Fold change from 
Treg population. (D) qPCR of healthy donor PBMC (Leukopak) (D) qPCR of 
corresponding T cell populations from spleens of GFP-Foxp3 mouse. (D-E) qPCR were 
performed in triplicates, repeated X2-3. ***: p < 0.001, **: p < 0.01, *: p < 0.05, 
determined by one-way ANOVA, followed by Dunnett’s test. 
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Figure IV-4: Expression patterns of DUSP1 and DUSP4 in CD8 populations. 
(A-C) Scatter plots of RNA expressions represented by FPKM for DUSP1 and DUSP4 
expression in CD8 T cells from RNAseq of multiple tumor types; (A) prostate cancer, 
(B) glioblastoma, and (C) renal cell carcinoma. N = 12, 8, 6, respectively. (D, E)
Confirmation by qPCR for DUSP1 and DUSP4 in human and mouse; Fold change from 
naïve CD8 T cell. (D) qPCR of healthy donor PBMC (Leukopak). (E) qPCR of 
corresponding T cell populations from spleens of GFP-Foxp3 mouse. (D-E) qPCR were 
performed in triplicates, repeated X2-3. ***: p < 0.001, **: p < 0.01, *: p < 0.05, 
determined by one-way ANOVA, followed by Dunnett’s test. 
Figure IV-5: Selectively higher expression of RGS1 in TIL. 
(A-C) Scatter plots of RNA expressions represented by FPKM for RGS1 expression in 
CD4 and CD8 T cells from RNAseq of multiple tumor types; (A) prostate cancer, (B) 
glioblastoma, and (C) renal cell carcinoma. N = 12, 8, 6, respectively. (D, E) 
Confirmation by qPCR for RGS1 in human and mouse; relative expression to house-
keeping genes (18S). (E) qPCR of healthy donor PBMC (Leukopak). (D) qPCR of 
corresponding T cell populations from spleens of GFP-Foxp3 mouse. (D-E) qPCR were 
performed in triplicates, repeated X2-3. ***: p < 0.001, **: p < 0.01, *: p < 0.05, 
determined by one-way ANOVA, followed by Dunnett’s test. 
Figure IV-6: Gene-targeting strategies for the generation of conditional DUSP1 or 
RGS1 knockout mice. 
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(A) LoxP variant sites were introduced flanking exon 2 of Dusp1 gene. Those mice
were crossed to FlpE-expressing mice for neo removal. After making them homozygous 
for floxed alleles, those mice will be crossed to Cre-expressing mice to generate the 
knockout allele with a deletion of exon 2. (B) LoxP variant sites were introduced 
flanking exon 3 of Rgs1 gene. Those mice were crossed to FlpE-expressing mice for 
neo removal. After making them homozygous for floxed alleles, those mice will be 
crossed to Cre-expressing mice to generate the knockout allele with a deletion of exon 3. 
(Ozgene)
SUPPLEMENTARY FIGURE LEGENDS FOR CHAPTER IV: 
Supplementary Figure IV-1: Gating strategies for the sorting for RNAseq and 
qPCR.  
Representative Gating strategies of human PBMC and TIL for CD4 populations (A) and 
CD8 populations (B). The following population were sorted out: PBMC CD4 naïve 
(CD4+CD25LowCD127+/-CCR7+CD45RA+CD27+CD28+), PBMC CD4 regulatory T cell 
(Treg)(CD4+CD25HiCD127Low), PBMC CD8 naïve (CD8+CD45RA+CD45RO-
CD27+CD28+), PBMC CD8 antigen experienced (CD8+ CD45RA-CD45RO+), TIL CD4 
regulatory T cell (CD4+CD25HiCD127Low) and TIL CD8 antigen experienced 
(CD8+CD45RA-CD45RO+). PBMC CD4 naïve and PBMC CD8 naïve (both from fresh 
and frozen samples) were activated ex-vivo using anti-CD3/anti-CD28 activation beads 
for 72 hours. 
(*Flow images for Supplementary Figure IV-1 were modified from Nirschl, Muroyama, 
Drake et al.) 
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Supplementary Figure IV-2: qPCR for DUSP1 and DUSP4 in human with TIL-
Treg. 
(D, E) qPCR of healthy donor PBMC (Leukopak) and of RNA extracted from renal cell 
carcinoma TIL-Treg. RNA expression, relative expression to house-keeping genes (18S) 
for DUSP1 (D) and DUSP4 (E), respectively. qPCR were performed in triplicates.  
Supplementary Figure IV-3: qPCR for DUSP1 and DUSP4 in B16/F10-bearing 
GFP-Foxp3 mice. 
(A) Gating strategies for the isolation of naïve CD4/8 T cells, antigen-experienced CD8
T cells and Treg from spleens and tumors of B16/F10-bearing GFP-Foxp3 mice. 
Representative images from tumor samples are shown. (B-M) q Confirmation by qPCR 
for DUSP1 (B-D), DUSP4 (E-G), RGS1 (H-J), and RGS16 (K-M). PCR of 
corresponding T cell populations from spleens and TIL of B16/F10-bearing GFP-Foxp3 
mouse. (B, E, H, K) Overview, relative expression to house-keeping genes (18S), (C, F, 
I, L) Fold change expression from naïve CD4 T cells, (D, G, J, M) Fold change 
expression from naïve CD8 T cells. qPCR were performed in triplicates. ***: p < 0.001, 
**: p < 0.01, *: p < 0.05, determined by one-way ANOVA, followed by Dunnett’s test. 
(Note: CT value for TIL-derived or DLN-derived samples were high (>34), which made 
the data preliminary.) 
Supplementary Figure IV-4: Investigating the roles of DUSP1/4 and RGS1 in vitro. 
(A) Experimental design (plan). Human PBMC (Leukopak) were transfected with
siRNA oligos via electropolation, then Treg were isolated, followed by in vitro 
suppression assay. (B) Time course of Foxp3 knockdown for different siRNA oligos 
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(Foxp3-1, 2, 3). (C) Expression of RNA 24 hours post siRNA transfection for different 
oligos (DUSP1: D1-1,2, DUSP4: D4-1,2, RGS1: R-1,2,3, Helios: H1-1, 2, 3). (D-E) In 
vitro micro-suppression assay using human PBMC (LeukoPak). (D) Representative 
figure of the in vitro suppression assay (preliminary). Tresponder cells (naïve CD8 T 
cells: 2000 / well) were analyzed for their proliferation based on the dilution of CTV 
dye. (B) Quantitative plots represent percent suppression at the indicated Treg:T 
responder ratio. A representative experiment of a total of three independent replicates is 
shown. (N = 3 per group, repeated 2x.) % Suppression = (1-(DI of the sample)/(DI of 
the average of “No Treg”))*100 (*DI=division index). 
(Note: (A-C): Summer rotation medical student Victoria Huang (my mentee).) 
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Gene Targeted Locus of the Dusp1 Gene
Wildtype Locus of the Dusp1 Gene
Gene Targeted Locus after flp mediated neo removal 
Gene Targeted Locus after Cre mediated deletion of exon 2 
Figure IV-6: Gene-targeting strategy to create Dusp1 floxed mice.
Figure IV-6A
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Gene Targeted Locus of the Rgs1 Gene
Wildtype Locus of the Rgs1 Gene
Gene Targeted Locus after flp mediated neo removal 
Gene Targeted Locus after Cre mediated deletion of exon 3 





Supplementary Figures for Chapter IV:




(A,	B: modified from Nirschl, Muroyama, Drake et al.)
Supplementary Figure IV-1
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Gating strategies of tumor-bearing GFP-Foxp3 mouseA
Supplementary Figure IV-3
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